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Abbreviations and Definitions 
Abbreviation Full form 
ATT Antitubercular Therapy 
BCG Bacille Calmette-Guerin 
DOTS Directly-Observed Treatment, Short course 
DS Drug Susceptible 
DR Drug Resistant 
EPTB Extra Pulmonary Tuberculosis 
H Isoniazid 
HPLC High Performance Liquid Chromatography 
H.I.V. Human Immuno -Deficiency Virus 
IGRA Interferon-Gamma Release Assay 
LC-MS Liquid Chromatography-Mass spectrometry 
MDR-TB Multidrug-Resistant Tuberculosis 
MIC Minimum Inhibitory Concentration 
PAE Post- Antibiotic Effect 
PK Pharmacokinetics 
PTB Pulmonary Tuberculosis 
R Rifampicin 
TB Tuberculosis 
TST Tuberculin Skin Test 
TU Tuberculin Units 
WHO World Health Organization 
XDR-TB Extensively Drug-Resistant Tuberculosis 
ZN Ziehl–Neelsen Stain 
DEFINITIONS 
Failure to respond: A case of paediatric TB who fails to have bacteriological 
conversion to negative status or fails to respond clinically / or deteriorates after 12 
weeks of compliant intensive phase, provided alternative diagnoses/ reasons for nonresponse 
have been ruled out. (RNTCP 2012)  
Relapse: A case of paediatric TB declared cured/completed therapy in past and has 
(clinical or bacteriological) evidence of recurrence.  
High HIV burden: High HIV burden is a country or sub national units within a country 
either with HIV prevalence in adult pregnant women of more than >1% or HIV prevalence 
among TB patients is >5% (WHO Rapid advice 2010) 
Multidrug resistant or MDR TB:   refers to an isolate of Mycobacterium. tuberculosis that 
is resistant to atleast isoniazid and rifampin and possibly additional chemotherapeutic agents. 
 Extensively drug resistant TB or XDR TB: refers to an isolate of Mycobacterium 
tuberculosis that is resistant to at least isoniazid, rifampin, and any Fluoroquinolone as well 
as either Aminoglycosides (Amikacin, Kanamycin, or Capreomycin or both.    
Pharmacokinetics (PK): It is the study of kinetics of drug movement in the body. It includes 
the study of kinetics of absorption, distribution, metabolism and excretion. 
Cmax: It is the maximum plasma concentration achieved after a doing, Similarly, Tmax is the 
time point at which maximum concertation is achieved 
Volume of distribution or VD: It is a hypothetical volume that would accommodate the 
entire drug in the body if the concentration throughout was same as in the plasma. It is 
expressed in litres. 
Ke: It is the elimination rate constant that reflects the fraction of drug removed from the 
given compartment per unit of time (per hour) 
Half-life Time taken for a drug for its plasma concentration to be reduced to half of its 
original value (hours). 
Clearance: It is the theoretical volume of plasma from which the drug is completely cleared. 
AUC: It is the area under plasma concentration time curve. Done by measuring the plasma 
concentrations of a drug at various time points after dosing. Expressed as mg.hr/L.  
ABSTRACT 
TITLE 
Comparison of drug concentration of isoniazid and rifampicin between daily and 
intermittent anti-tubercular (ATT) regimen, in children treated for tuberculosis. 
BACKGROUND 
The currently recommended doses of antitubercular (ATT) drugs in children are 
extrapolated from adult pharmacokinetic studies.  For children with tuberculosis, the 
Revised National Tuberculosis Control Programme (RNTCP) in India advocates 
treatment through an intermittent drug regimen, whereas the World Health 
Organisation (WHO) recommends daily therapy, at least during intensive phase of the 
ATT. The WHO recommendation is particularly for areas with high HIV prevalence and 
high drug resistance such as India. Sub-therapeutic ATT concentrations could lead to 
failure of therapy, prolonged infectiousness and the emergence of drug resistance.  
AIM 
To compare the serum concentrations of isoniazid and rifampicin between the daily and 
intermittent ATT regimen, in children treated for tuberculosis. 
To determine the pharmacokinetics of isoniazid and rifampicin in children treated for 
tuberculosis.
OBJECTIVES: 
 To measure the drug exposure as the area under the concentration time curve to six
hours (AUC0-6h) for both isoniazid and rifampicin in children treated by either daily
or intermittent ATT regimen.
 To determine the inter-patient variability in serum concentration for both isoniazid
and rifampicin in the above children.
 To determine the basic pharmacokinetic parameters, such as first-order absorption
and elimination rate constants, half-life, lag time and apparent volume of distribution
in the total study population.
 To create a population pharmacokinetic model using the Pmetrics package for ‘R’ for
isoniazid and rifampicin.
METHODS 
Children aged 2 to 16 years, initiated on either daily or intermittent (thrice weekly) ATT were 
recruited into the study, after obtaining informed consent. Patients were dosed based on the 
RNTCP guidelines (2004).  Towards the end of the intensive phase, blood specimens were 
collected pre-dose, followed by 0.5, 1, 1.5, 2, 2.5, 4 and 6hrs post-dose. The concentrations 
of isoniazid and rifampicin were analyzed using a validated LC-MS/MS and HPLC assays, 
respectively. Results were analyzed using non parametric methods with R version 3.1.2. A 
non-parametric model was developed using Pmetrics package for R ©. 
RESULTS 
The median dose (mg/kg) for isoniazid was 10.13 versus 8.10 (p=0.005) in the intermittent 
and daily dose regimens respectively. When compared to the current RNTCP (2012) 
guidelines, 83 % of patients were prescribed a dose below the recommended.  The C0 (μg/mL) 
was below the limit of detection versus 0.15 (p=0.0009) for the intermittent versus daily 
regimen. The Cmax (μg/mL) was 6.8 versus 6.86, C2(μg/mL) was 5.1 versus 5.54 and C6
(μg/mL) was 2.01 versus 2.18 respectively in intermittent versus daily regimen, none of these 
were significantly different.  Median AUC0-6hrs(mg.hr/L) was 22.18 versus 24.55 (p =0.879) 
in the intermittent versus daily regimen.  
The median dose (mg/kg) for rifampicin was 10.26 versus 10.77 in the intermittent and daily 
dose regimens respectively.  When compared to the current RNTCP (2012) guidelines, 62 % 
of patients were prescribed a dose below the recommended.  C0 (μg/mL) was below the limit 
of detection, versus 0.01 (p=0.4) for intermittent versus daily regimen.  Cmax(μg/mL) was 
6.19 versus 5.59, C2(μg/mL) was 4.3 versus 4.4 and C6(μg/mL) was 1.01 versus 1.68 
respectively in the intermittent versus daily regimen, however there was no significant 
difference.  Median AUC0-6h (mg.hr/L) was 16.87 versus 16.51 (p =0.879) in intermittent 
versus daily regimen.  
CONCLUSION: 
All the patients (except 2) had isoniazid Cmax above 3μg/mL (recommended range: 3-
6μg/mL) and 83% of the patients had rifampicin Cmax less than recommended range (8-
24μg/mL) 31% of the patients had a very low Cmax for rifampicin, which is <4µg/ml.  Cmax
has a strong correlation with AUC0-6h  in both regimens for both isoniazid and rifampicin. (r= 
0.889 and 0.97 for isoniazid; r=0.89 and 0.98 for rifampicin).  
Only 20% of the patients had Cmax at 2hrs for both isoniazid and rifampicin. Hence 
pharmacokinetic studies in children for both drugs should include earlier time points to 
capture the Cmax accurately.  
Dose of rifampicin does not appear to have a correlation with the exposure. Also rifampicin 
has a high interindividual variability (% CV of 54 % for AUC and 59% for Cmax). Therefore, 
we recommend the use of TDM for patients on rifampicin (especially for the patients who do 
not respond adequately or respond slowly). 
KEYWORDS: Tuberculosis, isoniazid, rifampicin, regimens, children 
Reference for therapeutic range of isoniazid and rifampicin: 
Verhagen LH, et al. Trop Med Int Health. 2012;17:1449-56
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INTRODUCTION 
 
Tuberculosis (TB) is an infectious disease caused by a bacterium which belongs to the 
Mycobacterium tuberculosis complex group.  The main member of the group causing TB is 
Mycobacterium tuberculosis (1). Globally, in adults , TB is the second leading cause of 
death due to an infectious disease, after Human Immunodeficiency Virus (HIV) (2),(3).  The 
disease burden is very high in developing countries such as India compared to  developed 
countries (4).  
 
According to the World Health Organisation (WHO) , in 2013, there were 5,00,000 cases 
of TB in children out of which there were 80,000 deaths (excluding the children who are 
co-infected with HIV) (4). The exact incidence of childhood tuberculosis in India is not 
available (6). Estimates say that India accounts for 27% of all the childhood TB worldwide 
(7)(8).  
 
The treatment of tuberculosis consists mainly of antitubercular drugs. To prevent emergence 
of drug resistance, a combination of antitubercular drugs is used. Treatment consists of a 
combination of isoniazid, rifampicin, ethambutol and pyrazinamide as first line regimen. 
Treatment of drug resistance poses challenges as the second line drugs are less efficacious, 
costlier and toxic. Also, treatment of drug resistance is for prolonged durations with lesser 
cure rates (5). 
 
Current doses of antitubercular drugs used in children are extrapolated from adult 
pharmacokinetic studies (9).  However, children are not miniature adults, hence adequacy 
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of doses has to be established in children using pharmacokinetic studies, especially in the 
Indian population. 
 
Amongst the factors that determine the response to antitubercular therapy, one of the most 
important is drug-related factor. These drug-related factors include compliance, adequacy 
of the dosage, duration of therapy and altered pharmacogenomics that may affect the 
pharmacokinetics of a drug. Decreased blood concentrations of anti-TB drugs can result in 
inadequate response or delayed response, prolonged periods of infectivity, acquired drug 
resistance and if the bacillus is not cleared adequately, it can result in reactivation of disease 
at a later time in life (10). 
 
There are two main regimens used in the treatment of childhood tuberculosis viz. daily and 
intermittent wherein the medication is given on daily basis and thrice a week basis 
respectively. In this study we have compared the drug exposure [in terms of Cmax (µg/mL) 
and area under concentration time curve or AUC0-6h (mg.hr/L)] for both isoniazid and 
rifampicin between the two Anti Tubercular Therapy (ATT) regimens. In addition, we also 
compared the pharmacokinetic parameters and clinical outcome at the end of two months 
for isoniazid and rifampicin in the two regimens. We have developed pharmacokinetic 
population models for isoniazid and rifampicin in children on ATT.   
 
The results of this study can provide an understanding of the exposure of drug 
concentrations of isoniazid and rifampicin between the two commonly used regimens in 
India, as well as the possible correlation between drug concentration and clinical outcome   
at the end of intensive phase. 
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AIMS AND OBJECTIVES 
 
AIM 
To compare the serum concentration of isoniazid and rifampicin between daily and 
intermittent ATT regimen, in children treated for tuberculosis. 
To determine the pharmacokinetics of isoniazid and rifampicin in children treated for 
tuberculosis 
 
OBJECTIVES 
1. To measure the drug exposure as area under concentration time curve to 6 hours 
(AUC0-6h) for both isoniazid and rifampicin in children treated by either daily or 
intermittent ATT regimen.  
2. To determine the inter-patient variability in serum concentration of both 
isoniazid and rifampicin in above children 
3. To determine basic pharmacokinetic parameters, such as absorption and 
elimination rate constants, half-life, lag time and apparent volume of distribution 
– in the total study population 
4. To create a population pharmacokinetic model using the “Pmetrics” package for 
‘R’ for isoniazid and rifampicin. 
  
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
EPIDEMIOLOGY OF TUBERCULOSIS 
 
Tuberculosis is a disease known for a very long time. Radiocarbon evidence from an extinct 
bison date it  to 17,000  years ago (11).  It was found in unearthed skeletons from Egypt that 
were dated to be 4000 years old (12). Hippocrates described TB as ‘Phthisis’. The epidemic 
of tuberculosis first occurred in Europe in the 16th and 17th centuries, called as “White 
Plague”. Thereafter ,there was a slow spread  to the other parts of the world (12),(13).  With 
improvement in living conditions and the advent of antitubercular drugs, the disease came 
under control (showing a drop in both the mortality and morbidity rates ) in developed 
countries, but remains a major health problem in developing countries (12). Globally in 
adults, TB is the second commonest cause of death due to an infectious disease following 
Human Immunodeficiency Virus (HIV) (2). In 1993, tuberculosis was declared a global 
emergency by the WHO (14). Even today it is considered a ‘silent killer’(14). 
 
According to the WHO, in the year 2013 there were 9.0 million cases of tuberculosis 
globally i.e., 126 cases / 1,00,000 population (4).  However, the distribution of cases was 
not uniform throughout the world (see Figure 1). Around 56 % of the above cases occurred 
in Asia and 29 % in Africa. India, along with five other countries (China, Nigeria, Pakistan, 
Indonesia and South Africa) accounted for the highest number of incident cases.  India and 
China accounted for 24 % and 11 % of global tuberculosis burden, respectively (4). 
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Figure 1 Estimated incidence rates of tuberculosis in 2013. Adapted from WHO Global 
Tuberculosis Report 2014. 
 
At present, one third of the world's population is infected with tuberculosis.  An untreated 
sputum-positive patient with TB can infect 10 to 15 people every year.  Around 5 to 10 % 
of people infected will develop active tuberculosis during their lifetime.  The risk is much 
higher in patients co-infected with HIV (10,11).  In immunocompetent adults, pulmonary 
tuberculosis (PTB) is the commonest form, only about 10 % of patients have extra 
pulmonary tuberculosis (EPTB). However, in immunocompromised patients,  EPTB can 
account for 40 to 50 % of cases (15,16).  In contrast, 25 to  35 %  of immunocompetent 
children develop EPTB (17,18).  Apart from this, there is a growing drug resistance to first 
line drugs resulting in MDR (Multi-drug resistance) and XDR (Extensively-drug resistance) 
strains (see Definitions).  India, according to WHO, comes under the category of  high TB 
burden, high MDR burden and high HIV burden country (19).(see Figure 2)  
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Figure 2 Notified MDR TB cases in 2013; Adapted from: WHO MDR Report 
 
BURDEN OF TUBERCULOSIS IN CHILDREN 
According to the WHO, there were 5,50,000 cases of TB occur in children each year of 
which there are 80,000 deaths.  Since this data is exclusively of children who were not  co-
infected with HIV ; the actual number of total cases will be certainly more than this (4).  
Globally, the total incidence of childhood tuberculosis is 6 %  to 10  %  (20) ,but it can be 
as high as  40 % in endemic countries (21)(22).   Over ten million children were orphaned 
in 2010 as a result of parental deaths caused by TB and out of these orphaned children it is 
not known how many were infected or diseased by TB (19).  TB is one of the major causes 
of childhood mortality (9). 
 
In India and other developing countries, children below 15 years of age account for 40 to 
50 % of population posing a greater number of children at risk to tuberculosis (19), (17). In 
India alone, there are roughly 440 million children (0 to 14 years) accounting for 30.4 % of 
the entire population (23)(24). In 2013, 63,919 new cases of paediatric TB were notified 
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accounting for 5% of all TB notified under the Revised National Tuberculosis Control 
Programme (RNTCP) which has been a constant over the past 5 years (25).   However, these 
figures may be an underestimate because of multiple reasons (9), the main reason being 
predominant smear-negative pulmonary tuberculosis in children and more extra pulmonary 
tuberculosis than adults (26)(27). Hence, the diagnosis of TB in children needs a high index 
of suspicion and careful clinical examination (9,26). 
 
Accurate estimation of TB in children is important because the majority of paediatric TB 
occurs within one year following infection, and hence the presence of TB in children is 
taken as an indicator of ongoing transmission of M. tuberculosis in the community (28)(29).   
 
Most of the national programmes report only smear positive tuberculosis, thus, childhood 
tuberculosis is usually underestimated. Apart from this, most studies of prevalence exclude 
children. Children who die of other causes like malnutrition and pneumonias may have 
undiagnosed tuberculosis (30)(31).  Estimates show that the number of children with TB 
are much higher than estimated by the WHO (8)(7).  The diagnosis and treatment of 
childhood tuberculosis is really a challenging task.  Therefore , the focus of World TB day 
in 2012 was on childhood tuberculosis , aiming at increasing the awareness (32).  Following 
this, child friendly formulations were developed (33), and in 2013 the roadmap to eliminate 
childhood tuberculosis was launched (34). 
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AETIOLOGY 
Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis. It belongs to 
Order Actinomycetales, Genus Mycobacterium and Family Mycobacteriacea (1).  The first 
member identified in this family was Mycobacterium leprae discovered by Armaller Hansen 
in 1868.  The name “tuberculosis” was coined by J. L. Schonlein in 1839 (35).  
Mycobacterium tuberculosis was discovered and isolated by Robert Koch in 1882 (36) and 
he was awarded with the Nobel Prize for the same in 1905 (37). 
 
The name “Mycobacterium” means “fungus like bacterium” due to the mould or fungus like 
appearance when cultured on liquid media. The unique feature of this “Genus 
mycobacterium” is that all members of this family contain mycolic acids in their cell wall. 
Family Mycobacteriacea is a very diverse family; it has obligate pathogens like M. leprae 
as well as free-living forms like nontuberculous mycobacteria in aquatic habitats. Similarly, 
the conditions required for optimal growth are different in different species. There are five 
mycobacteria in the Mycobacterium tuberculosis complex: M. tuberculosis, M. bovis, M. 
africanum, M. microti, and M. canetti. Out of all these, Mycobacterium tuberculosis is the 
most important cause of human tuberculosis in both adults and children , in India (38). 
 
Structural characteristics 
Mycobacterium tuberculosis is non-motile, non-capsulated, pleomorphic, slim slightly 
curved or straight rods, and weakly gram-positive bacilli with 0.2 to 0.6 μm by 1.0 to 10 μm 
in size. They are obligate aerobes, and appear beaded or clumped in stained clinical 
specimens on examination. These mycobacteria grow best at 37-41C; however, growth is 
slow with a generation time of 12-24 hr. 
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The mycobacteria have a cell wall made up of peptidoglycolipid. The mycolic acids are 
important constituents of the cell wall and are made up of high molecular weight α alkyl, β 
hydroxyl fatty acids linked to lipoarabinomannans. At least  15%  of the genes encode the 
cell wall constituents (12).  Due to the presence of mycolic acids in their cell wall, they have 
unique staining properties. They are not readily stained with the common dyes, but once 
stained they resist decolourisation even with strong acids. This pattern of resistance to 
decolourisation is called as ‘acid fastness’ and they are called as acid fast bacilli (AFB). The 
commonest acid fast method used to stain AFB is by using Ziehl Neelsen stain (ZN). 
PATHOGENESIS 
The sequence of events following exposure to tuberculosis were described in the literature 
reviews done in 20th century, mainly before chemotherapy came into vogue. These studies 
were conducted with the help of clinical examination and radiological studies (28).  
Infection with Mycobacterium tuberculosis is called ‘latent tuberculosis infection’ or 
‘LTBI’.  All patients infected with Mycobacterium tuberculosis may not develop active 
disease.  The term, ‘tuberculosis’ or ‘TB’ is used synonymous with the disease. 
Transmission of M. tuberculosis from person to person is by airborne mucus droplet nuclei,  
through particles 1-5 μm in diameter that contain AFB (39).  The transmission is more if 
the patient has a smear-positive disease with an extensive upper lobe infiltration, as well as 
produces thin copious sputum on coughing (40).   
 
The unique feature of mycobacterium is to go in a state of dormancy. This is facilitated by  
the following features (41) 
 escape from phagocytosis by reprogramming macrophage  
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 formation of well-defined granulomata which create a well confined environment to 
escape from host 
 capacity to shut down its own metabolism without any replication called as 
“dormant forms”.  None of the first line ATT drugs are active against such dormant 
bacteria. 
Sequence: 
After exposure to an infectious case of tuberculosis, the bacilli are deposited in the terminal 
alveoli. Tubercle bacilli multiply initially within alveoli and alveolar ducts. Most of the 
bacilli are killed by the innate immunity, but some survive within non-activated 
macrophages, which carry them through lymphatic vessels to the regional lymph nodes.     A 
localised inflammatory reaction takes place, called as “Ghon Focus”. The bacilli drain via 
the local lymphatics to the regional lymph nodes. There can be also local lymphadenopathy; 
mainly of hilar lymph nodes. Paratracheal, nodes are also involved. The localised 
lymphadenopathy, together with Ghon focus and lymphangitis is called a “primary 
complex”. Haematogenous spread occurs from the primary complex and the bacillus are 
deposited in the target organs. 
 
The future course of the disease depends on dynamic balance between host immunity and 
virulence of pathogen. The innate immunity of the child may eliminate the bacillus. or  the 
bacillus may overcome the innate immunity and cause the infection to progress and convert 
to active disease.
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Factors, which determine the chances of getting infected and or progression of infection 
to active disease (some factors are common to both adults and children) 
 
1. Poverty: Tuberculosis is a disease of poor, not only at the community level but also 
at national level. This is evident from the incident rates in different countries.    Far 
greater incidence is noted in underdeveloped and developing countries than in 
developed countries (4)(42).  The relationship between poverty and tuberculosis 
forms a vicious cycle; because, each one perpetuates the other; poverty causes lack 
of access to healthy food, overcrowding, delay in accessing health care services. 
Tuberculosis in turn causes poverty by morbidity, reducing household income etc. 
(40,42–45).  Hence, the theme of World Tuberculosis day 2002 was “Stop TB, fight 
poverty” (46). 
 
2. Household food insecurity: ‘Food insecurity’ means not having access to sufficient 
food at all times. Food insecurity increases the risk for tuberculosis in children due 
to micronutrient deficiency (47).  
 
3. Age: The age at which infection occurs has a direct impact on the rate of progression 
of disease from the time of infection.  After infection, 20 – 30 % of the infected 
infants develop disease, 5 % develop in the 3 to 5-year age group and only 2 % 
develop in the 5 to 10-year age group (48,49)(50).  Infants and children less than 4 
years have maximum risk of suffering from severe forms of disease and even 
succumbing to it (51). 
 
4. Household conditions: Exposure to active case of pulmonary tuberculosis, 
especially a smear positive case at home, increases the chances of children getting 
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infected (52,53).  Similarly sharing the bed-room along with an infected case; 
especially the one having multiple zone tuberculosis with prolonged periods of 
cough, is also associated with increased risk of  infection children (34, 35). 
 
5. Indoor air pollution (IAP): This includes exposure to biomass fuels and tobacco 
smoke. Exposure to passive tobacco smoke and solid fuel smoke has shown to 
reduce the mucosal integrity and increased chance of tuberculosis especially in 
families where adults have pulmonary tuberculosis, either smear positive or smear 
negative (24, 34–37). 
 
6. Ventilation: It is well established that children living in poorly ventilated homes are 
at greater risk of being infected. Good ventilation i.e., opening windows and doors 
has shown to reduce transmission in both adults and children (58–60)(61). 
 
7. Vitamin D levels: Vitamin D modulates a variety of regulatory systems such as host 
defence, inflammation, immunity, and repair. The exact role of Vitamin D in the 
development of tuberculosis is not conclusive because of contradictory results from 
different studies (some favouring and some not) (47,62–65)(66). 
 
8. Malnutrition: Both malnutrition and tuberculosis interact mutually. The exact 
mechanism of malnutrition predisposing to tuberculosis is not known. Some 
probable mechanisms are that malnutrition leads to secondary immunodeficiency 
(especially cell-mediated immunity) that increases the host's susceptibility to 
infection. Both, protein-energy malnutrition and micronutrient deficiencies increase 
the risk of tuberculosis. On the other hand, in patients with tuberculosis, it leads to 
anorexia, nutrient malabsorption and altered metabolism leading to wasting.  
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Malnutrition not only increases the risk of getting tuberculosis but also raises the 
severity of disease leading to delayed recovery and higher mortality rates than in 
cases of well-nourished patients (47, 48). 
 
9. HIV infection: Children infected with HIV are at a higher risk of being infected 
with tuberculosis.  Also the chances of drug resistant tuberculosis are more in HIV 
infected children (69–71)(72). 
 
10. Other factors: Risk factors apart from those listed above include, prevalence in the 
community, cultural practices around childcare, BCG vaccination, strain of infecting 
mycobacterium, genotype of host, climatic conditions, behavioural conditions at 
home such as alcoholism, helminth infections etc.,(27)(40).
 
ORGANS INVOLVED: 
 
The primary site of TB is lung, called as pulmonary tuberculosis or PTB. Extra pulmonary 
tuberculosis or EPT is when TB affects any other organ other than lungs. Sometimes both 
forms coexist. The common extra pulmonary sites affected by tuberculosis are lymph nodes, 
meninges, heart, bones and joints, kidneys, pleura etc. The primary complex mainly affects 
parenchyma and regional lymph nodes. Sometimes children can have only lobar pneumonia 
without lymphadenopathy. If the initial infection is extensive liquefaction of lung 
parenchyma can lead to cavity formation (39). 
 
The hilar lymph nodes if extensively involved can cause air-way obstruction by 
compressing the regional bronchus. This can lead to focal hyperinflation and atelectasis. 
Very rarely, the inflamed caseous node attaches to endobronchial wall and erode through it 
  
Page | 17  
 
causing fistula track. Erosion of a parenchymal focus of tuberculosis into blood or lymphatic 
blood vessels causes dissemination of bacillus resulting in miliary or disseminated TB. 
CLINICAL FEATURES 
The symptoms and signs depend on the organ involved. Most of the time children have 
constitutional symptoms such as malaise, anorexia, weight loss, and fever. Sometimes 
children can be completely asymptomatic but show extensive disease involvement on X ray 
examination (73) or present as pyrexia of unknown origin ( PUO )(39). 
 
Organs commonly affected and some manifestations  (74)(75) 
 Lung --               chronic persistent cough with or without expectoration 
 Lymph node --   lymphadenopathy with rubbery or matted lymph nodes, can 
                                 lead to abscess  
 Pleura --             Pleural effusion with breathlessness and pain over chest 
 Heart --               Pericarditis and pericardial effusion, can manifest as heart 
                           failure 
 Brain --              TB meningitis with features of raised intracranial pressure; 
                           tuberculoma 
 Abdomen --        pain in abdomen 
 Joints --              Painless effusion   
 Bone --               chronic osteomyelitis 
 Renal --              Sterile pyuria or haematuria 
 Skin --                lupus vulgaris, papulo-necrotic lesions 
 Eyes --                iritis, optic neuritis
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DIAGNOSIS 
The diagnosis of tuberculosis in children is mainly clinical. It is based on the WHO 
guidelines and National Guidelines on diagnosis and treatment of Pediatric tuberculosis 
2012 formulated as the Revised National Tuberculosis Control Programme (RNTCP) 
(54,55). All efforts should be made to confirm the diagnosis (see Annexure I and II). Young 
children (especially 5 to 10 years of age) may sometimes present with clinically silent (but 
radiographically apparent) disease (78) 
 
The main features helpful for diagnosis are 
1. Persistent fever lasting for more than 2 weeks 
2. Persistent cough lasting for more than 2 weeks 
3. Documented loss of weight/no weight gain (Weight loss of > 5 % of the highest 
documented weight in the last 3 months is considered as significant) 
4. Very young children can show features of failure to thrive, reduced playfulness and 
fatigue. 
5. History of contact with an infectious TB case, should be elicited always (76,78,79).          
 
The main investigations required for diagnosis are: (80)(81) 
 
Tuberculin Skin Test or Mantoux test: A positive TST is defined as an induration of 10 
mm or more. The optimal strength of tuberculin 2 TU (RT 23 or equivalent) should be used 
for diagnosis in children. However, this is not a very sensitive test.  
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Chest X Rays: Radiological changes highly suggestive of pulmonary TB are 
Hilar/paratracheal lymphadenitis with or without parenchymal lesion; Miliary TB, 
fibrocavitary pneumonia can also be present. 
 
Sputum smear examination: It is a very easy and reliable test for detection of 
mycobacteria in sputum. Sputum smear examination for acid-fast bacilli should be done by 
taking early morning expectorant specimens using ZN staining. However, in young children 
sputum production may not be there/may be inadequate and other methods like Gastric 
lavage or induced sputum should be used for AFB detection. But in children, only 15% of 
cases are positive for sputum acid fast bacilli and among them only 30-40% yield a positive 
mycobacterium culture (76,79). 
 
For lymph node tuberculosis: Smear examination for AFB by ZN Staining of the pus from 
discharging sinus / aspirate from lymph node should be done. Biopsy and Histopathological 
examination of the tissue will show granulomatous changes suggestive of tuberculosis. 
 
AFB Culture: Culture of sputum or aspirate from lymph node is considered the gold 
standard for the detection of Tuberculosis. With culture, drug susceptibility testing (DST) 
can also be done and resistance determined.  
 
Xpert MTB/RIF assay: This is a PCR (Polymerase Chain Reaction) based assay for the 
detection of Mycobacterium tuberculosis as well as the rpoB mutation for rifampicin.  This 
single test is useful for both diagnosis as well as for detection of drug resistance. This test 
is more sensitive and specific, as well as consumes less time when compared to any other 
test. Hence, the WHO recommends it as the test of choice when suspecting MDR-TB or 
HIV-associated TB, and conditionally recommends it as a replacement or add-on test to 
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conventional microscopy and culture in children and for extra-pulmonary specimens. 
However, it is costly and not easily available. In addition, a negative test does not rule out 
the disease (67). 
 
Other tests: There is no role of IGRA (Interferon Gamma Release Assays), BCG or other 
serodiagnostic tests for the diagnosis of tuberculosis in children as these tests cannot 
differentiate between infection and disease (63). However, they may be useful in 
diagnosing the latent infection along with other investigations. 
TREATMENT 
The mycobacterial species is inherently resistant to most of the available antibacterial 
compounds such as aminoglycosides, β lactam antibiotics due to its unique structural and 
functional properties. This is mainly due to the presence of thick hydrophobic mycolic acid 
cell wall leading to decreased permeability, presence of efflux pumps and production of 
inactivating enzyme (83,84). 
 
The treatment of tuberculosis consists mainly of antitubercular drugs. The role of nutrition 
supplementation, besides ATT is inconclusive (85).  The drugs used in the treatment of 
tuberculosis are classified into five groups by the WHO.  As we proceed from Group 1 to 
Group 5, the efficacy decreases and adverse effects increase (except for recently approved 
drugs which are placed in Group 5).  Hence Group 1 is the most efficacious and most 
tolerated group whereas Group 5 comprises those drugs, which are of unproven efficacy or 
unproven toxicity, or proved efficacy but their long-term safety is not yet established.  
Newly approved drugs are also classified under group 5.
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CLASSIFICATION OF ATT DRUGS 
(86)(5) 
Group 1: First-line oral anti-TB drugs isoniazid, rifampicin, ethambutol,  
                         pyrazinamide, Other rifamycins like rifabutin, rifapentine. 
 
Group 2: Injectable anti-TB drugs (injectable agents or parenteral agents)    
                         streptomycin, kanamycin, amikacin capreomycin 
 
Group 3: Fluoroquinolones (FQs) levofloxacin, moxifloxacin, gatifloxacin,  
                         ofloxacin   
 
Group 4:  Oral bacteriostatic second-line anti-TB drugs: ethionamide,  
                         prothionamide, cycloserine, terizidone, p-aminosalicylic acid 
 
group 5:    linezolid, clofazimine, amoxicillin/clavulanate, imipenem/cilastatin,  
                          meropenem, high-dose isoniazid, thioacetazone,  clarithromycin.     
                          Newly approved drugs, such as bedaquiline and delamanid.      
 
Pharmacology of isoniazid 
Isoniazid was synthesised by Meyer and Malley in 1912.  However, its antimycobacterial 
properties were not recognised until 1950.  For the first time, it was used in clinical trials 
conducted in 1951 for the treatment of tuberculosis. Later it was developed by Squibb, 
Hoffman La Roche and Bayer in 1952. Since then it has become a key drug in the treatment 
of TB. isoniazid is chemically isonicotinic acid hydrazine (INH). It is a small molecule 
(C₆H₇N₃O) with a molecular weight of 132  (87)(88). 
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Mechanism of action  
Isoniazid is a rapidly acting bactericidal drug.  The exact molecular mechanism of its action 
is not known, but it acts mainly by interfering with cell wall and nucleic acid synthesis (89). 
It is a prodrug; it enters the bacillus by passive diffusion. Inside the bacillus, a 
multifunctional catalase peroxidase enzyme encoded by KatG acts upon it. This results in 
the production of active drug, an ‘isonicotinoyl radical’. The isonicotinoyl radical reacts 
with mycobacterial NAD and NADP and forms about a dozen adducts. The main adduct is 
nicotinoyl NAD isomer which inhibits the InhA (enoyl acyl carrier protein reductase) and 
KasA (β ketoacyl acyl carrier protein synthase). (see Figure 3)  Both InhA and KasA, are 
most essential enzymes for mycolic acid synthesis (89).  More specially, InhA is a member 
of fatty acid dehydrogenase complex 2 involved in mycolic acid synthesis (90). 
 
The second important adduct is nicotinoyl NADP isomer. This inhibits dihydrofolate 
reductase and interferes with nucleic acid synthesis. Other products of KatG activation 
include superoxide radical generation which also contribute to bactericidal action (90). It 
also interferes with carbohydrate and lipid metabolism. 
 
Mechanism of resistance: 
Resistance can be primary or secondary. The frequency of mutation in tuberculous bacillus 
1 in 106 bacilli. Since one tubercular cavity contains at least 107 to 109 bacilli, using only 
isoniazid selects the mutant strain leading to rapid development of resistance. 
 
The mechanism of resistance to isoniazid is as shown hereunder: 
 Mutation in Kat G or deletion of Kat G 
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 Overexpression of genes for InhA  
 Overexpression of genes for ahpc 
 Mutation in the KasA and KatG genes 
 Loss of NADH dehydrogenase II activity 
 Activation of efflux pumps 
Kat Mutations along with rpoB gene mutation finally leads to development of multidrug 
resistant strains. 
 
Pharmacokinetics: 
It is explained using two compartmental model with first order absorption and elimination 
kinetics (91). Isoniazid is well absorbed orally, with bioavailability of 90-100 % following 
oral administration. Food and antacids delay absorption (92).  It has a plasma protein 
binding of around 10% and penetrates blood brain barrier. Isoniazid undergoes metabolism 
mainly in the liver and gut mucosa. Phase 2 metabolism by N-acetyltransferase 2 or NAT 2 
plays a major role in its metabolism as it is subjected to genetic polymorphisms.  NAT 2 
converts isoniazid to acetyl isoniazid (major metabolite) which can further metabolise to 
monoacetylhydrazine.  Isoniazid can also undergo hydrolysis and form acetyl hydrazine. 
Both monoacetyl hydrazine and acetyl hydrazine, can be further metabolised to hepatotoxic 
acetyl hydrazine ketone acetylonium ions by CYP2E1. (see Figure 3) These hepatoxic ions 
are cleared by Glutathione system.  Three main genotypes are identified based on NAT 2 
expression, as rapid, intermediate and slow acetylators.  Fast acetylators may not achieve 
adequate therapeutic concentrations, especially with intermittent doing effect (83), whereas 
slow acetylators may be at high  risk of adverse effects (93).
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Figure 3 - Activation and Metabolism of isoniazid. Reference: Goodman and Gillman 12th 
edition 
 
 
 
Adverse drug reactions: 
Isoniazid is a well-tolerated drug. Few important adverse effects are peripheral neuritis, 
hyper sensitivity reactions and hepatotoxicity.  Rarely, mental abnormalities such as 
euphoria, psychosis can occur.  Pyridoxine supplementation helps in preventing the CNS as 
well as peripheral neuritis side effects. 
Drug Interactions: It inhibits enzymes CYP2C19, CYP3A4 and CYP2D6, induces 
CYP2E1.Hence it can interact with drugs which are metabolised by above enzymes. 
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Microbial pharmacokinetics/pharmacodynamics (PK/PD):  The bactericidal effect of 
isoniazid correlates well with AUC0-24h over minimal inhibitory concentration (MIC) and 
the suppression of resistance correlates with Cmax over MIC. Hence both peak concentration 
and overall exposure are important (87). 
 
Pharmacology of rifampicin 
Rifampicin belongs to rifamycins group of antibiotics.  It was discovered in 1958 and 
introduced in 1968 for the treatment of tuberculosis (94).  The other members of this group 
are rifapentine and rifabutin.  These are macrocyclic antibiotics with a chromophoric 
naphtohydroquinone group that is spanned by a long aliphatic bridge with an acetyl group 
at position C25. (see Figure 4) 
 
Mechanism of action: rifampicin enters the bacillus in a concentration dependent manner.  
It diffuses freely into cells including macrophages.  It then binds with very high affinity to 
β sub unit of DNA dependent RNA polymerase (encoded by rpoB gene) and forms a stable 
drug enzyme complex which suppresses RNA synthesis (94)(95). 
 
Mechanism of resistance: 
 Due to alteration of target rpoB gene, mainly mutation at codons 526 and 531 of 
rpoB. 
 Mutation in DNA repair mechanisms (mut and ogt) leading to MDR strains 
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Figure 4 : Structure of rifampicin; Reference: Goodman and Gillman 12th edition  
 
 
Pharmacokinetics 
It is explained using a one compartment oral model.  It is rapidly absorbed from 
gastrointestinal tract, but to a variable extent. Bioavailability is around 68% (96).  
Absorption is not affected by antacids but is reduced by food.  Therefore, it is always 
advised to take rifampicin on an empty stomach (87). It is metabolised by microsomal β 
esterases and cholineserases, and CYP 3A4 enzymes. Removal of acetyl group at position 
C25, and formation of 25-o-desacetyl rifampicin as well as 3–formyl rifampicin takes place. 
The metabolite is active (has 10% of anti-mycobacterial action).  It is a strong inducer of 
cytochrome enzymes; it induces CYP3A4, CP2C9, CYP 1A2 and CYP2C19 mainly, and in 
the process, induces its own metabolism. 
 
PK/PD relation 
Rifampicin bactericidal action is mainly related to AUC over MIC ratio whereas the 
suppression of resistance is linked to peak concentration over MIC and not the total time 
duration above MIC.  It has a long PAE of around 5 days (97). 
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Adverse drug reactions 
 Hypersensitivity reactions such as fever, rash are common. Rarely haemolysis, renal 
insufficiency and acute renal failure. 
 Gastrointestinal upset. 
 Hepatitis.  
 Nonspecific CNS symptoms. 
 “Flu like syndrome” results when rifampicin is administered on intermittent basis. 
It is manifested as fever with chills, eosinophilia, interstitial nephritis, etc. 
 Harmless orange discolouration of all secretions, such as urine, saliva, sweat etc. 
 Overdose results in “Redman” syndrome. 
 
Drug Interactions: Due to its potent CYP enzymes inducing ability, rifampicin is prone 
for lot of drug-drug interactions.  It mainly interacts with warfarin, sulphonylureas, non-
nucleoside reverse transcriptase inhibitors, protease inhibitors, oral contraceptives, 
glucocorticoids, cyclosporine, statins etc. 
It comes under category C for pregnancy; isoniazid is considered safe during pregnancy. 
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OVERVIEW OF REGIMENS FOR THE TREATMENT OF TB 
History of Regimens and Role of DOTS 
Initially in 1950, when antitubercular drugs were discovered, daily monotherapy was the 
main mode of treatment.  Soon, as the number of relapse cases increased, it was evident that 
monotherapy leads to emergence of drug resistance.  Following this, combination regimens 
were introduced and were found to be highly effective.  Later, many in vitro studies showed 
that first line antitubercular drugs have a long post antibiotic (PAE) effect, (for example 
isoniazid has a PAE of around 120 hrs) and intermittent regimens were started (98–100).  
The effectiveness of thrice weekly regimen was found equal to that of daily regimen in 
many randomized controlled clinical trials including from India (101)(102).  To overcome 
the problem of non-compliance, directly observed therapy was started.  In 1993, WHO 
approved DOTS as the standard mode of therapy for TB.  Since then, there was an increase 
in the cure rates and drastic reduction in the mortality due to TB.  India is one of the major 
countries which implements DOTS under RNTCP programme. 
 
However, lately, with the increasing problem of drug resistance (DR), increasing MIC 
values even for drug susceptible organisms, HIV infection etc., the daily regimen was found 
to be associated with lesser relapse rates and less chances of acquired drug resistance (as 
relapse is directly related to the number of doses administered) (103). Hence, many 
countries are now using daily regimen (at least during the intensive phase)(104). India too, 
has a high MDR burden and high primary resistance to isoniazid (15-18 %) (97). 
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Dosage and Regimens for the treatment of tuberculosis in children 
Every country has its own national guidelines (based on WHO guidelines) for their 
tuberculosis control programme. Doses for children are based on body weight and largely 
extrapolated from adult pharmacokinetic studies (5).  Some studies favour dosage based on 
body surface area as it achieves better plasma concentrations when compared to dosing 
based on body weight  (105),(106). 
WHO guidelines for the treatment of childhood tuberculosis(107) 
 First guidance by WHO for the treatment of tuberculosis in children came in 2006. 
The doses were  
Isoniazid (H) 5 mg/kg for daily and 10 mg/kg in intermittent; maximum dose 300 
mg/day and  
Rifampicin (R) 10mg/kg mg for both the regimens; maximum dose 600 mg/day. 
 
The WHO released the “Rapid Advice” for the treatment of tuberculosis in 2010 and 
published the updated second guidance in 2014. Here the doses of isoniazid and rifampicin 
were increased (77,108). 
H    10 mg/kg (range 7–15 mg/kg); maximum dose 300 mg/day  
R     15 mg/kg (range 10–20 mg/kg); maximum dose 600 mg/day 
 
Regarding the usage of daily or intermittent schedules, WHO opined that daily regimen, is 
preferred over intermittent regimen for the initial 2-month intensive phase of treatment 
especially in areas with high HIV prevalence, patients known to be affected with HIV and 
in areas of high isoniazid resistance (77).  The intermittent regimen can be given during the 
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continuation phase ,living in  settings with well-established DOTS but, not for those from 
an area with high HIV prevalence (15)(77).  Some studies suggest that using intermittent 
therapy has a higher risk of treatment failure and develop multidrug-resistant tuberculosis 
(109)(110). 
The revised national tuberculosis control programme (RNTCP) was launched in India in 
1997 based on the World Health Organization advised directly observed treatment strategy 
(DOTS), with treatment given three times a week. 
 
Based on the above guidelines, RNTCP revised the doses in India, in 2012 which are 
as follows: 
 The following are the revised doses (mg per kg of body weight per day adjusted accordingly 
for thrice-weekly regimens) (see Table 1 for the summary of revised RNTCP doses). It has 
to be noted that though the revision was made in 2012 the new boxes were not 
implemented during the period of this study 
 H   10 mg/kg (max 300 mg/day)  
 R     10-12 mg/kg (max 600 mg/day) 
 
However, RNTCP in its revised recommendations states that the intermittent regimen as the 
main mode of therapy, unless the patient is admitted and seriously ill.  In such patients daily 
supervised therapy can be given till they get discharged and intermittent regimen started 
(111). 
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Table 1  ATT Dosage according to Revised RNTCP 2012 guidelines 
 
 
 
However, there are no large scale RCTs in children showing superiority of one regimen over 
other (101)(112). The main limitation of many studies is inadequate follow up; as relapse 
tend to occur only after a significant time period and also since patients can become 
symptomatic after a period of wellbeing long-term follow-up is essential to establish the 
actual superiority of one regimen over the other. 
 
Previous Guidelines 
(Weight band in kg) 
 The isoniazid and 
rifampicin dose 
Revised Guidelines 
(Weight band in kg) 
 
The isoniazid and 
rifampicin dose 
6-10 75mg 6-8 100 mg 
11-17 150 mg 9-12 150 mg 
18-25 225 mg 13-16 200 mg 
26-30 300 mg 17-20 250 mg 
>30 Adult dosing 21-24 300 mg 
 25-30 400 mg 
>30kg Adult dosing 
Adult Dosing: 600 mg of isoniazid, 450 mg rifampicin, 1200mg ethambutol, 
1500 mg pyrazinamide. 
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Two Cochrane reviews in children comparing both the regimens concluded that, as of now 
(i,e  2013 and 2009), it is not known which regimen is superior and said further studies will 
be needed  (113)(114). 
 
 In a systematic review the long term efficacy of DOTS regimen for tuberculosis was 
assessed and it was concluded that “relapse rate is significantly higher in patients treated 
intermittently when compared to those treated daily”.  Also additional concerns include risk 
of rise in MDR tuberculosis and poor response in patients with HIV co infected with 
tuberculosis (111)(104,109,115)(116).  In light of the above evidence, RNTCP recently 
(March 2015) decided to start daily therapy using fixed drug combination (FDC), though it 
is not yet implemented(117). 
 
Role of BCG 
BCG stands for Bacille Calmette Guerin. .BCG vaccines are live attenuated vaccines 
derived from an attenuated strain of Mycobacterium bovis that was develop by Calmette 
and Guerin (118).  According to recent systematic analysis , it was showed that vaccination 
helps in both preventing the infection as well as halts the  progression of disease (119). 
According to Indian paediatric guidelines for vaccination, BCG is routinely given to all  
new-borns (120).
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Previous pharmacokinetic studies of isoniazid and rifampicin in 
children:  
Most of the PK studies are done in the recent 15 years (few are summarised in Table 2) on 
the following page 
Table 2 Few Previous PK studies in children on ATT 
Reference Drug* Dose Regimen Cmax** AUC** 
McIIeron et al (121) H 4-6mg/Kg daily 2.39 5.97 
McIIeron et al  (122) H 8-10mg/kg daily 5.71 14.13 
H S Schaaf et al   (123) R 9.61mg/kg daily 6.92 18.07 
 
Verhagen et al (124) H 5.2mg/kg daily 1.9 8.8 
Verhagen et al (124) R 10.4mg/kg daily 5.1 20.6 
Ramachandran et al(125) H 10mg/kg intermittent 6.3 26.7 
Ramachandran et al(125) R 9.4mg/kg Intermittent 7.0 30.0 
 
*H stands for isoniazid; R stands for rifampicin. 
** The units for Cmax and AUC are µg/mL and mg.hr/L respectively. 
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HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) 
 
High Performance liquid chromatography (HPLC) is a technique where compounds in a 
mixture or in a biological matrix can be identified, separated and quantified. The technique 
utilises the principle of column chromatography i.e. a different partitioning between the 
mobile and stationary phase. The commonly used HPLC is based on the principle of reverse 
phase chromatography, where the stationary phase is a nonpolar packed material held in a 
steel column. The mobile phase is polar consists of solvents such as methanol or acetonitrile 
and most often combined with buffers. There are five main components of HPLC (see 
Figure 5) 
 
1. Column:  The column is the stationary phase in HPLC. It comprises of a polished 
stainless steel tube usually 50-300mm long and 2-5mm in diameter.  Within this is held a 
silica-based matrix. Silica is very polar and hence suitable for normal phase 
chromatography.  The silica is made non polar by using bonding technology. Here the 
reactive silanols on the surface of silica are converted to nonreactive silanols using 
hydrophobic bonded phases such as C18, C12, C6, cyclohexyl, phenyl, alkyl phenyl etc. 
Even after this, a few residual silanol groups persist which can be further bonded using “end 
capping” and CL (CH3)2SiCH3 is one of the commonly used end capping agent. 
 
Pump:  This pumps the mobile phase and must be extremely smooth and constant in its 
action. Depending on the analyte the pump can be adjusted to deliver an isocratic or gradient 
flow of solvent. 
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Injector: can be automated or manual, for the injection of extracted drug specimen for 
analysis. 
 
Detector: several detectors exist but the most common is the UV- Visual detector: which 
was employed for this study. 
 
Software and Data system: computer for setting the parameters of the HPLC for example, 
column temperature, wavelength, flow rates and gradient or isocratic elution.  The 
chromatograms and their details are recorded, data analysed and concentrations determined. 
 
'Figure 5 HPLC  - Source : Clinical Pharmacology Unit, CMC ,Vellore. 
 
 
 
LEGEND: 1 column, 2 mobile phase solutions ,3 rack for keeping specimens,4 detector, 
and 5 computer.
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LC-MS/MS 
LC-MS/MS Stands for Liquid chromatography Mass Spectrometry. LC-MS/MS is a tandem 
mass spectrometer which has an additional collision cell where parent ion can be fragmented 
into daughter ions.  It works on the principle of mass by charge ratio (m/z).  Since the m/z 
ratio is specific for a given molecule, even trace amount of chemicals can be detected with 
high accuracy. Coupling LC-MS/MS to HPLC or UPLC utilises the quantification part of 
the former and separation part of the latter. 
 
The main steps are summarised below in simple manner: 
 
Ionisation: since the MS relies on m/z ratio, conversion of analyte to ionised form 
is a perquisite before analysis. Depending on the instrument, there are many ways 
by which ionisation can be achieved, the commonest one used is atmospheric 
pressure ionisation (API).  API ionizes samples under atmospheric pressure 
conditions, which makes is useful to remove solvents outside a vacuum. The 
commonest technique used in API is electrospray ionisation (ESI).  High voltage 
and high temperature that is applied to the solvent will help in the vaporization and 
ionization of the analyte of interest.  ESI is the gentlest ionization method available, 
so it is used for polar, least volatile, or thermally unstable compounds. Most of the 
generated ions are protonated or deprotonated molecules. 
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 Analyser: The ions from ionised sample are focused into the analyzer portion (mass 
spectrometer) where separation takes place based on m/z ratio.  
 
 Data acquisition: It is done using a system linked with software (mass lynx in this 
case). 
 
Figure 6  LC-MS/MS/MS coupled to UPLC   
 
 
 
LEGEND:  1 –UPLC coupled to LC-MS/MS, 2-Mass spectrometer ,3 Computer,4 Nitrogen 
generator ,5 –Argon cylinder. 
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JUSTIFICATION FOR THE STUDY 
 
1. In spite of the WHO recommending daily treatment regimens especially during intensive 
phase, in high HIV burdened countries such as India, RNTCP to date continues to advocate 
the intermittent regimen for TB. 
 
2. Most patients in low resource settings are treated as per the RNTCP guidelines and 
prescribed the intermittent regimen for the treatment of tuberculosis, with an increased 
possibility of being treated with inadequate doses of ATT and as a result having an 
unsatisfactory exposure to the anti TB drugs. This is especially true if the patient is missing 
even 1 or 2 doses. 
 
3. Sub-therapeutic concentration of drugs may lead to prolonged infectivity, delayed 
response and poor treatment outcome such as relapse and acquired drug resistance in the 
treatment of tuberculosis. 
 
4. A recent study from Chennai (125) that included only children prescribed intermittent 
therapy for TB, reported that 90% of children had low Cmax of rifampicin with a failure rate 
of 21%. 
 
5. In addition, pharmacokinetics of ATT defines more rapid drug clearance in children, 
which may favor a daily regimen for tuberculosis in children. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
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METHODOLOGY 
The study was approved by the Institutional Review Board of the Christian Medical 
College, Vellore (IRB Number -8892, dated 09.06.2014). 
 
STUDY DESIGN 
This was an open label, prospective cohort observational study in the paediatric population. 
This study was done at the Clinical Pharmacology Unit, (Department of Pharmacology and 
Clinical Pharmacology) Christian Medical College (CMC), Vellore, in collaboration with 
the Department of Community Health and Development (CHAD), which is a secondary 
care centre located in Bagayam, Vellore and Child Health Unit 3 (Department of Child 
Health), located in the CMC Hospital (CMCH), Vellore.  
 
A total of 37 consecutive children (2-16 years of age) who satisfied the inclusion criteria 
were included in the study. Out of these, 26 children were on intermittent regimen and 11 
children were on daily regimen.  Tuberculosis was diagnosed as per the RNTCP and WHO 
guidelines (22) (see Diagnosis section ). Doses for intermittent therapy were based on the 
RNTCP guidelines and for daily therapy based on WHO rapid advice (2010) guidelines. It 
is to be noted that treatment of intermittent therapy has not yet been incorporated the dosing 
strategy recommended in RNTCP 2012 guidelines because of the delay in implementation 
from the RNTCP. 
 
SETTING 
Patients were recruited from both CHAD, Bagayam and Department of Child Health, 
CMCH. There is an exclusive DOTS (Directly Observed Short Course, Chemotherapy) 
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centre in Bagayam. The children diagnosed at CHAD are routinely initiated on the DOTS 
regimen which is given as thrice weekly (intermittent ATT regimen), whereas children 
diagnosed in the Department of Child Health are routinely initiated on the daily ATT 
regimen, where the medicine is given on a daily basis unless, due to financial constraints, 
they are referred to the DOTS centre for the intermittent ATT regimen.  
INCLUSION CRITERIA 
 Parents willing to give written informed consent and child assent (if applicable) 
 Children aged between 2 years to 16 years 
 Children who are diagnosed with either pulmonary TB or TB lymph node  
 Children on prophylaxis on both isoniazid and rifampicin at therapeutic doses 
 Parents willing to bring their children at the end of the intensive phase 
 Parents and child willing to stay in the hospital for 7 hrs on the day of study 
 Children newly started on ATT (Category 1) 
EXCLUSION CRITERIA 
 Children with other forms of tuberculosis other than pulmonary or lymph node 
tuberculosis 
 Children who are HIV positive 
 Children diagnosed with co-morbidities such as drug induced hepatitis, renal 
dysfunction or liver dysfunction 
 Cases where treatment regimen was changed during intensive phase of therapy 
(from intermittent regimen to daily regimen or vice-versa) 
 Relapsed cases (category 2) 
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The study was in 2 parts. In part 1, patients were recruited at the time of initiation of ATT 
and followed up till they completed the 2-month intensive phase, when both the 
pharmacokinetic measurement was done and clinical outcome was observed.  
Part 2 was observational study where the outcome at the end of treatment completion (end 
of continuation phase) was noted. 
 
The diagnosis of tuberculosis, the decision to start on ATT, the dosage and the regimen 
selection was entirely at the clinician’s discretion. No changes were made to the routine 
practice in both the centres. After the patient was started on ATT, written informed consent 
was obtained from the parents and / or assent from children aged above 8 years (see 
Annexure III). A diary (see Appendix IV) was given at the time of taking consent to assess 
compliance of the patient. The parents were asked to note the day and time at which 
medication was given. The parents were also counselled about the importance of 
compliance. The parents were also requested to avoid over the counter medication. 
At the time of recruitment, the age, height and weight were noted. Height and weight were 
also noted at the end of the intensive phase and at the end of the treatment completion. The 
nutritional status of children was assessed using the WHO Anthro and Anthro Plus Software 
for children less than 5 years and greater than 5 years respectively 
 
DURING THE INTENSIVE PHASE OF ATT 
From the day of initiation, the pharmacokinetic study was done after 45th dose and before 
60th day for children on daily regimen and after 19th dose to before 24th dose in case of 
children on intermittent regimen. One week prior to the day of the pharmacokinetic study, 
the parents were contacted by telephone or directly when they visited the DOTS centre. The 
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timing of the ATT drugs was confirmed.  All the instructions which were to be followed 
were given.  Parents were reminded about the instructions one day before the day of study 
by telephone. Very few patients were admitted one day prior to the day of study due to 
issues related to difficult transport facilities from their residence to the hospital. The 
important instructions include: 
 No food intake was allowed after 11 pm. 
 Child should be fasting on the day of study (No milk or milk containing products 
were allowed) 
 Juice (non- milk containing) was allowed 
 They have to report at 7.30 am 
 They should bring all the medicines which they were taking in the past 2 months 
 Bring the compliance diary 
On the day of the pharmacokinetic study, after the patient reported to the child health 
treatment room in CMCH, the compliance diary was checked. Careful history was taken 
regarding any illness in the preceding week (especially a history of diarrhoea or vomiting) 
and intake of any other co-medication. 
 
An insyte was placed in one of the veins of upper limb and trough specimen collected. The 
time of trough collection was noted. The same dose which the patient was receiving 
throughout the intensive phase was then administered under direct observation and the time 
was noted in the proforma (see Annexure II).  After the patient had swallowed the medicine, 
blood specimens were taken at 0.5hr, 1hr, 1.5hr, 2hr, 2.5hr, 4 hrs and 6 hrs after the intake 
of isoniazid and rifampicin.  Around 1.5- 2mL of blood was collected during each specimen 
into a 2 mL EDTA (ethylene diamine tetra acetic Acid) vacutainer. This was followed by 
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0.5 -1mL of heparin lock flush solution. Prior to the next sample collection 0.5 -1 mL was 
discarded to remove the heparin lock flush solution, following which the subsequent blood 
specimen was collected. 
 
The specimen collected was immediately placed on ice-packs in a thermocol box and 
transferred to the Clinical Pharmacology Unit. The specimen was immediately centrifuged 
at 1400 rpm for 5 minutes and the plasma was separated (within 15 minutes of collection).  
Measures were taken to ensure a quick transport to the Clinical Pharmacology Unit and 
thereby separation of the plasma without further delay, as both isoniazid and rifampicin are 
unstable if left in blood. 
 
After separation, isoniazid was analysed on the same day using LC-MS/MS whereas 
rifampicin was analysed using HPLC.  Rifampicin, if not analysed on same day was stored 
at -80C freezer till analysis was done. The child was allowed to have breakfast after 1 hour. 
 
The result of the study was conveyed to the concerned co-investigator. The child was 
followed after the study till the entire duration of treatment was over. 
Methodology for acetylator status determination for isoniazid: 
It is known that the pharmacokinetics of isoniazid depends on acetylator status. Therefore, 
phenotypic acetylator status was determined using an isoniazid half-life as described by 
Miscoria et at 1988.  According to this method, isoniazid  half-life of less than 1.8 hrs was 
classified as a fast acetylator , and greater than 1.8 hrs as slow acetylators (124). 
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METHODOLOGY FOR ASSAY DEVELOPMENT AND VALIDATION 
HPLC Method for rifampicin 
Chemicals and Reagents: 
Rifampicin pure powder was obtained from Tocris Bioscience products. Pure Nevirapine 
powder which was used as internal standard (IS) was obtained from CIPLA technologies, 
Goa. acetonitrile, potassium hydrogen phosphate, potassium dihydrogen phosphate were 
HPLC grade and were obtained from Thermo Fisher Scientific Private Limited, Mumbai, 
India. 
 
Equipment: 
The assay was developed and validated using HPLC, Waters Alliance e2695 system with 
separation module and detection in Waters 2489™, with a UV detector. 
HPLC column: Shiseido C18 column with 4.6 x 250 mm in dimensions, 5 µm particle size 
(Shiseido, Japan) was used. 
 
HPLC Conditions: 
Mobile phase: 61 % of 29 mM phosphate buffer, pH=7 and 39 % of acetonitrile. 
Volume of injection loop: 40 µL 
Isocratic elution 
Flow rate: 1.2 mL /min 
Sample temperature: 5⁰ C 
Column temperature: ambient 
Wavelength ( ):330 nm (UV detector) 
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Preparation of stock solution: 
Rifampicin: The concentration of rifampicin stock was 1 μg/µL or 1mg/mL. This was 
prepared by dissolving 1part of rifampicin pure powder in 1-part of methanol/ascorbic acid 
mix.   
Two sets of stock and working solutions were prepared, one for the standards and one for 
the QC’s. 
Methanol ascorbic acid mix: 4parts methanol and 1part of ascorbic acid. (1μg/ μL) 
Ascorbic acid:  1mg of ascorbic acid in 1mL of deionised water. 
Nevirapine (Final 1µg/µL): was used as internal standard. Nevirapine (2 μg/μL) is added to 
ascorbic acid (0.5 μg /μL) in a 1: 1 ratio.  
Preparation of plasma standards and quality control: The following working standards 
were prepared using above stock solution of rifampicin. 
Stock 1 (Primary stock):  rifampicin stock solution (1μg/ μL) 
Stock 2:  1 in 10 dilutions (0.1 μg/ μL) of the primary stock 
Stock 3: 1 in 100 dilutions (0.01μg/ μL) of the primary stock  
 
Preparation of Standards  
 
Std 10 μg/ mL   = 100 μL of stock 2 + 900 μL of calf plasma 
Std 7.5μg/ mL   = 75 μL of stock 2+ 925 μL of calf plasma 
Std 2.5 μg/ mL = 25 μL of stock 2 + 975 μL of calf plasma 
Std 1 μg/ mL    = 100 μL of stock 3 + 900 μL of calf plasma 
Std 0.5 μg/ mL = 50 μL of stock 3+ 950 μL of calf plasma 
Std 0.25 μg/ mL = 25 μLof stock 3+ 975 μL of calf plasma 
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Two quality controls were prepared as given below: 
QC 5 μg/ mL =     50 μLof 0.1 of stock 2 + 950 μLof calf plasma 
Qc 1.5 μg/ mL =   150 μLof 0.1 of stock 3 + 850 μLof calf plasma 
 
In order to prevent oxidation of rifampicin, ascorbic acid was added to standards and quality 
controls as suggested from previous published literature (127)(128).  To make 1mL of 
standard, add, 100 μL of 0.5 μg/μL of ascorbic acid and 900 μL of the required standard. 
For example: to make standard 10 μg/ mL:  add 900 μl of standard 10 μg/ mL and 100 μL 
of ascorbic acid. 
 
Extraction procedure:  
 About 2 mL of patient’s blood specimen was collected in EDTA tubes. Within 15 minutes 
of collection, the specimen was placed in centrifuge at 1400 rpm for 5 minutes. The plasma 
was separated into eppendorfs. From the plasma, 900 µL was taken into another eppendorf 
containing 100 µL of ascorbic acid (0.5 µg/µL).  
 
The Extraction was done by precipitation using acetonitrile as precipitating agent. To begin 
the extraction, 25 μL of Nevirapine (IS) was added into clean eppendorfs. Add 300 µL of 
plasma was added into the above eppendorf.  Following vortexing the eppendorf in a 
cyclomixer for 30 seconds, 400 μL of acetonitrile was added for protein precipitation. 
Following a quick vortex for 60 seconds, the eppendorf is placed in a centrifuge at 13000 
rpm (revolutions per minute) for 5 minutes. The supernatant is transferred to the injection 
vial from which 40 μL was injected into the HPLC for quantification.
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LC-MS/MS/MS Method for isoniazid 
Chemicals and Reagents: Isoniazid pure powder was obtained from Sigma Aldrich (CAS 
Number: 54-85-3), ammonium acetate from Fischer Scientific Labs. Formic acid and 
acetonitrile, was obtained from Sigma Aldrich (India).  Pure nicotinamide powder was 
obtained from Sisco Research Laboratories. The assay was developed and validated in a 
Waters Acquity LC-MS/MS coupled to Waters. UPLC Acquity.TM 
 
Isoniazid assay:  
Liusheng Huang et al method was used as a reference upon which our method was 
developed and validated (129).  The MS/MS was operated in positive ion mode using mass 
transitions of m/z 137.9 for isoniazid and 122.9 for IS (nicotinamide). The m/z of daughter 
ions was 120.9 and 105.9 respectively.  
 
The settings of the MS tune page were as follows, 
A Capillary voltage of 3.5 KV, cone voltage of 25 Volts, extractor voltage of 3 volts, and 
RF lens voltage of 0.1 V was adjusted. The source temperature and the desolvation gas 
temperature were 130ºC and 400ºC respectively.  The desolvation gas flow, the cone gas 
flow and the collision gas flow (Argon) were 800 L/hr, 50 L/hr, 0.16 mL/min respectively. 
 
UPLC conditions 
Column: Phenomenex Luna PFP (pentafluoro phenyl) 5 μm, 50 mm X 2mm. 
Mobile phase: 2 milliMolar ammonium acetate in water and acetonitrile with 0.1% formic 
acid. 
Flow: Gradient  
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Column temperature: 30 ⁰ C 
Sample temperature: 4.0C 
Loop size: 10 μl 
 
Preparation of stock and standards: 
Isoniazid stock: the primary stock was made by dissolving 1mg of isoniazid pure powder in 
1mL of de-ionised LC-MS grade water. 
STOCK 1: (1 μg/ μL):1μg of isoniazid pure powder dissolved in 1μL of water 
STOCK 2: (0.1 μg/ μL): made as 1in 10 dilution of stock 1   
STOCK 3: (0.01 μg/ μL):  made as 1 in 100 dilution of stock 1  
The above stocks were used in the preparations of standards. 
Internal standard: Nicotinamide (25 ug/mL) was used as internal standard in this assay.  
 
Preparation of tertiary standards: 7 standards and 3 Quality control were made. 
CC1 (.1 μg/ mL):     100 μL of stock 3 and add 900 μL of water. 
CC2 ( 2 μg/ mL):     200 μL of stock 3 and add 800 μL of water 
CC3 (5 μg/ mL):     50 μLof stock 2 and add 950 μL of water 
CC4 (10 μg/ mL):   100 μL of stock 2 and add 900 μL of water 
CC5 (20 μg/ mL):   200 μL of stock 2 and add 800 μL of water 
CC6 (50 μg/ mL):   50 μL of stock 1 and add 950 μL of water 
CC7 (70 μg/ mL):   70 μL of stock 1and add 930 μL of water 
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Quality controls: 
Low QC (3 μg/ mL)            300 μL of stock 3 and add 700 μLof water 
Medium QC (1.5 μg/ mL)    150 μL of stock 2 and add 850 μL of water 
High QC (6 μg/ mL):         60 μL of stock 1 and add 940 μL of water 
 
Preparation of plasma standards for extraction was performed using the tertiary standards. 
20 µL of the appropriate tertiary standards was added to 180 µL of plasma. The standards 
thus prepared were used for the extraction.  The concentration of the standards(µg/mL) are 
0.1, 0.2, 0.5, 1, 2, 5 and 7 µg/mL and the concentration of the quality controls low, medium 
and high were 0.3,1.5 and 6 µg/mL respectively. Two different stocks were used for the 
preparation of Standards and Quality controls. 
 
Two mL of patient’s blood specimen was collected in EDTA tubes and transported to the 
clinical pharmacology unit in thermocol boxes with ice packs. Within 15 minutes of 
collection, the specimen was placed in centrifuge at 1400 rpm for 5 minutes. The 
supernatant was separated and transferred into clean eppendorfs.  
 
Extraction procedure 
 The extraction was by precipitation method. To begin, 50 μLof internal standard was added 
to a eppendorf (nicotinamide 25 μg/mL). Then 100 μL of plasma was added into the 
eppendorf. The eppendorf was vortexed for 30 seconds. Following this, 350 μL of 
acetonitrile was added and vortexed for 60 seconds. The eppendorf was then centrifuged at 
13000 rpm for 5 minutes The supernatant was transferred into the vials and 10 μL was 
injected into the LC-MS/MS for quantification. 
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Assay Validation Principles 
Validation of an assay was done to ensure that the developed method can be successfully 
applied to analyse specimen. The validation was based on the FDA guidelines (130). 
1. Selectivity: Selectivity is the capacity of the developed method to identify and 
quantitate the analyte in the presence of other components in the specimen as in 
blood or any other biological matrix. 
 
2. Accuracy: The closeness of the obtained value from the method developed to the 
true value of the analyte. 
 
3. Precision: The closeness of individual measures of an analyte to each other when 
the method is performed multiple times on the same biological specimen. Intra batch 
and inter batch precision is established. 
 
4. Reproducibility: The assay is validated for its reproducibility. 
 
5. Recovery: It is comparison of detector response obtained when the same amount of 
analyte is added to a biological matrix versus the detector response when it is added 
in pure solvent. Matrix affect is also checked along with recovery. 
 
6. Calibration curve: Also called the Concentration response curve. It is the 
relationship between instrument response and a known concentration of analyte. 
 
7. Stability : The stability of analyte in the biological matrix at different storage 
conditions such as during transportation, at room temperature, in freezer, at -20C 
and  at -80C is checked. 
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STUDY FLOWCHART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                     
 
 
 
 
 
 
Positive 
Negative 
exclude 
Intensive Phase of TB treatment planned 
Daily ATT Regimen 
 dose of H & R noted 
Intermittent ATT Regimen 
dose of H & R noted 
Written informed consent 
Children presenting to either CHAD or Child Health 
Outpatient department who are screened for tuberculosis 
Diagnosis of tuberculosis – pulmonary or lymph 
node (including pleural effusion). Also, children 
on prophylaxis at therapeutic doses. 
Just before the end of intensive phase (2 months, +/- 15days), Pharmacokinetic 
study was done. Parents were contacted using telephone and instructions were 
given. 
No   Discontinue 
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.          
On the day of study, an insyte was inserted. After collection of trough, 
medication was given under observation (both isoniazid and rifampicin). 
Over a period of 6hrs, up to 8 specimens of 2 ml each were collected in 
EDTA tubes 
 
Specimen collected was placed in thermocol box with ice packs and 
transferred to Clinical Pharmacology Unit within 15 minutes of collection. 
 
In the Clinical Pharmacology Unit, plasma was separated and isoniazid and 
rifampicin was analysed using a validated LC-MS/MS/MS and HPLC 
method respectively. 
 
The results of analysis were conveyed to the concerned co-investigator or 
clinician. Dosage change if any was purely at their discretion. Results were 
analysed using R version 3.1.2 and Pmetrics.  
Population model was developed using Pmetrics package for R.  
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. PHARMACOKINETICS AND STATISTICAL ANALYSIS 
The peak concentration (Cmax) and time to reach Cmax (Tmax) were noted. 
Calculation of AUC  0-6h: After plotting the concentration (µg/mL) on y axis and time (hr) 
on x axis, the area under the curve is measured using trapezoid rule. The trapezoid rule 
measures the area of trapezoids (between two time points), as given by 
 
where C n and C n – 1 are concentrations measured at time points tn and tn-1 respectively. 
The summation of all trapezoids given the total AUC, 
 
Figure 7 Calculation of area under curve using trapezoidal rule 
 
X-axis: time in hours    Y-axis: concentration in µg/mL  
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SAMPLE SIZE CALCULATION 
To our knowledge, there were no studies in children similar to this study (when this study 
was started) from the Indian population, where comparison of pharmacokinetics was done 
in daily vs. intermittent regimen, to calculate the required sample size. Hence a pilot study 
was done aiming for 30 children in intermittent and 30 in daily regimen.
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FUNDAMENTALS OF POPULATION MODELLING 
(105) 
Population modelling comes under the preview of pharmacometrics. It is an evolving branch 
which mainly deals with personalised medicine, the main aim of modelling is 
“individualized therapy” so as to achieve maximum efficacy and minimum toxicity. 
Modelling is a mathematical method for predicting how a drug will behave in the body 
under given circumstances. It helps in answering some of the important questions like, 
“what is the initial dose most likely to achieve a safe and effective concentration in a given 
individual or in a set of population?” 
 
 All the pharmacokinetic data can be analysed using either a compartmental or a non-
compartmental approach.  
 The Compartmental analysis can be done using either Population models or 
Physiological models.  
 The population modelling can in turn be done using parametric or non-parametric 
methods.  
 
 The parametric methods are based on the assumption that all the pharmacokinetic 
data follows a normal distribution or any particular statistical distribution. These 
models mainly work by using mean and standard deviation of parameter and then 
applying Bayes theorem. An example of parametric modelling is NONMEM 
 
  
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The major advantages of parametric model: 
 Can distinguish between both interindividual and intraindividual variability  
 Can give confidence limits for a given parameter 
 Can accurately determine assay error 
Disadvantages of parametric models: 
 The main assumption that all the pharmacokinetic data assumes normal distribution 
may not be true as there can be subpopulation who are on extremes of range. 
 Assumes that a given parameter remains constant 
 Cannot handle sparse data or missing time points 
 Can be biased by sparse data or unbalanced date and overestimate or underestimate 
interindividual variability 
 
 The non-parametric methods do not assume that the pharmacokinetic data assumes 
a specific distribution. It measures not only mean and standard deviation, but takes 
into account each patient’s pharmacokinetic parameters called as “discrete joint 
density”. These parameters for example Ke elimination rate constants, Ka 
absorption rate constant, volume of distribution from each patient are taken into 
account and used to create “support points”. A probability is assigned to each 
support point which is then used for building the model. Modelling process is always 
iterative, till it converges. 
 
  
Advantages: 
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More precise as it can identify sub population 
Will consider many covariates which reflect the situation in clinical practise. 
Can handle missing time points 
Disadvantage: 
Cannot distinguish between interindividual and intraindividual variability. 
 
Pmetrics: 
“Pmetrics” is a package for a statistical software called “R”, which can analyse data using 
both parametric and non-parametric approach. Here the data is first used to get the estimate 
of the range of parameters and assay error; this is followed by non-parametric modelling. 
To do this a model file has to be made. A model file is actually a collection of equations 
and covariates which are taken as input. Covariates which are subject specific variables like 
Glomerular filtration rate (GFR), Body Mass Index (BMI), Age, gender, can be included if 
needed. 
  
RESULTS 
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RESULTS 
The results are discussed under three sections as given below. Appropriate tables and graphs 
are illustrated and discussed. 
 Results of assay validation for rifampicin and isoniazid  
 Results of pharmacokinetic analysis for isoniazid and rifampicin  
 A non-parametric model for isoniazid and rifampicin using Pmetrics 
RESULTS OF VALIDATION 
Results of rifampicin assay validation  
The aqueous standards were run for both analyte (rifampicin) and IS (nevirapine) to check 
their retention time.  The RT was found to be 3.7 minutes and 12.0 minutes for IS and 
rifampicin respectively. 
 
Selectivity: A specimen of plasma without rifampicin is known as a blank. It was collected 
from children who were not on rifampicin. Ten blanks were run to confirm that the assay is 
selective and that no interference is present (Figure 8). Similarly, 10 specimens were also 
run containing only the IS and no analyte (rifampicin). This is to confirm that there is no 
interference from internal standard at the retention time of drug. 
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Figure 8  Selectivity: Lowest standard versus blank specimens 
 
 
Calibration curve: was drawn to confirm the linearity of the assay.  A total of 6 calibrators 
and 2 quality controls(QCs) were used.  The standards were 10 µg/mL, 7.5 µg/mL, 2.5 
µg/mL, 1 µg/mL, 0.5 µg/mL, 0.25 µg/mL and the QC’s were 1.5 µg/mL, QC 5 µg/mL.  The 
standards and QC’s were prepared from two different standard stock solutions and the 
standards were checked for linearity.  The linearity was checked with the following equation 
:𝑌 = 𝑀𝑥 + 𝐶 ; Where ‘M’ is the slope and ‘C’ is the y-intercept. 
Figure 9 Calibration curve of rifampicin 
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Table 3    Data for Calibration curve of rifampicin 
Name of 
standard 
or QC 
(µg/mL) 
R.T (mts)    Area 
nevirapine 
R.T(mts)         Area         
rifampicin 
Ratio of area 
of drug over IS 
10 3.79 265926 12.04 192309 0.72 
7.5 3.72 289555 11.85 155720 0.54 
2.5 3.71 274833 11.87 48854 0.18 
1 3.72 271713 11.96 19341 0.07 
0.5 3.69 267166 11.91 9030 0.03 
0.25 3.69 271911 12.01 4730 0.02 
Qc(1.5) 3.76 270774 12.10 27851 0.1 
QC(5) 3.77 
 
263704 
 
12.10 
 
100888 
 
0.38 
 
Mts -minutes 
From the above data (Table 3), the slope. (0.0720) and intercept (0.0017) was calculated. 
The correlation coefficient was (R2) 0.999. The calculated low QC (1.5) was 1.41μg/mL 
and high QC (5) was 5.30μg/mL and both were within acceptable limits. The same 
calibrators and QCs were run on each day of patient specimen analysis. 
 
To conclude, the calibration curve was linear from 0.25μg/mL to 10μg/mL  (see Figure 9  
and 10.)  
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Figure 10 Chromatogram showing Calibration curve of rifampicin 
     
 
Intraday variability (Same batch, same day): This was performed by extracting three 
different concentrations, each five times and analysing using HPLC. The results are 
expressed in terms of %CV (coefficient of variation) for calculating precision. A percentage 
CV of less than 10% is acceptable. In addition, an accuracy of within 10 % of the original 
value is acceptable   However, for the lowest concentration, an accuracy and precision of 
up to 15% is considered acceptable. 
 
 For the concentration, 5µg/mL, the mean (standard deviation or SD) was 5.22µg/mL 
(0.071) and %CV of 1.36 %.  The accuracy was within 5% of the original value. 
(see Appendix II and Figure 11).  
 For the concentration, 7µg/mL, the mean (SD) was 7.44µg/mL (0.085) and %CV 
(imprecision) was 1.14%.  The accuracy was within 6 % of the original value. 
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 For the concentration, 10µg/mL, the mean (SD) was 10.5µg/mL (0.15) and %CV of 
1.45%. The accuracy was within 5% of the original value. 
 
Figure 11 Five different extraction of concentration 5µg/mL 
 
     
 
Figure 12 Five different extractions of cncentration 1.5 µg/mL 
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1.5) Inter Day variability (Same batch, different days) 
This was determined by repeating the extractions, on a different day, of the same 
concentrations measured on Day 1. On day 2 also, the standards and QCs were extracted 
five times, and the accuracy and precision were calculated in relation to day 1. 
For the concentration, 7 µg/mL, the mean (SD) was 6.935 (0.048) and % CV of 0.7 %. The 
accuracy was within 2 % of the original value.  
For the concentration, 0.7 µg/mL, the mean (SD) was 0.67 (0) and % CV of 0 %. The 
accuracy was within 4% of the original value.  
For the concentration, 5 µg/mL, the mean (SD) was 5.62 (0.143) and % CV of 2.55 %. The 
accuracy was within 11% of the original value. (see Appendix II) 
 
1.5) Reproducibility: of the assay was tested by re-injecting five times from the same 
extracted specimen. After one extraction, the specimen is placed in an auto sampler and re-
injected 5 times. 
The mean (SD) was 5.36 (0.05) and% CV was 1.0 % for concentration 5µg/mL  
The accuracy was within 4 % of the original value  
The mean (SD) was 7.232(0.06) and   % CV was 0.9%   for concentration, 7µg/mL (see 
Figure 14).  The accuracy was within 8 % of the original value. 
The chromatograph for concentration 1.5µg mL is shown in Figure 13. 
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Figure 13 Chromatogram showing Reproducibility of concentration 1.5 µg/mL . 
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Stability: Stability was checked using patient specimens. The specimen, which was 
immediately extracted and analysed, was compared with the specimen, which was left on 
the bench top without extraction for five hours. After extraction, this bench top sample was 
immediately analysed. (see Table 4) 
Rifampicin plasma specimen was stable when stored at -80C. Similarly, the stability of 
plasma standards and stock solution was checked. The rifampicin plasma standards and 
stock solution were found to be stable for 5 months. 
 
Table 4 Benchtop stability of rifampicin 
Actual 
Concentration (µg/mL) 
Measured µg/mL – 
Extracted and analysed 
immediately 
Measured µg/mL 
(Left on bench top for 5 
hrs. and then extracted 
and analysed) 
10 9.89 9.78 
0.5 0.43 0.43 
 
Recovery: It was assessed by comparing the detector response of spiked specimens with 
known amount of analyte in water, versus the same amount of analyte spiked in plasma. 
This was checked for 3 standards and 2 QC. 
The recovery was 100 % for concentration 7 µg/mL with a % CV of 0 %. 
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Results of isoniazid assay validation 
Calibration curve: Seven Standards and 3 QC were used as calibrators. They are CC 1, 
CC2, CC3, CC4, CC 5, CC6, CC7 (of concentrations 0.1 µg/mL, 0.2µg/mL, 0.5 µg/mL, 
1.0µg/mL, 2.0µg/mL, 5.0µg/mL, 7.0µg/mL respectively) and QC of 6.0 µg/mL, 1.5µg/mL, 
0.3 µg/mL (see Table 5 and Figure 15.). See Figure 16 for picture of LC-MS detector 
response.  The curve was linear from 0.1 to 10 µg/mL 
 Table 5 Calibration curve of isoniazid 
Name of standard R.T(mts)              Area 
Internal Standard 
R.T(mts)            Area 
isoniazid 
Ratio of area of 
drug over area of 
IS 
CC1 1.22 
 
14368.9 
 
1.21 
 
944.5 
 
0.066 
 
CC2 1.22 
 
14278.0 
 
1.21 
 
1857.5 
 
0.13 
 
CC3 1.22 
 
14299.1 
 
1.21 
 
4513.6 
 
0.316 
 
CC4 1.22 
 
14664.7 
 
1.21 
 
9566.5 
 
0.652 
 
CC5 1.22 
 
14793.3 
 
1.21 
 
18876.3 
 
1.276 
 
CC6 1.22 
 
14204.7 
 
1.21 
 
46160.8 
 
3.25 
 
CC7 1.22 
 
14246.6 
 
1.21 
 
62865.6 
 
4.413 
 
CC8 1.22 14608.9 
 
1.21 90893.4 
 
6.222 
 
High QC 1.22 
 
14122.1 
 
1.21 
 
90893.4 
 
3.89 
 
Medium QC 1.22 
 
14523.3 
 
1.21 
 
13698.9 
 
0.943 
 
Low QC 1.22 14394.9 1,21 2626.6 0.182 
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Figure 16 Detector response in LC-MS/MS/MS for isoniazid and IS 
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Accuracy and precision: It was checked by running five different extractions from same 
stock for 3 different concentrations. 
The mean(SD) was 0.29 (0.0122) and % CV was 4.22 (see Appendix III). 
 
Consistency: was checked by injecting from the same vial after a single extraction.  
For the concentration, 0.3µg/mL, the mean(SD) was 0.29 (0.008) and a % CV of 2.76 %.  
 
Stability: Stability was checked for stock, standards and plasma samples. The stock was 
found to be stable for 6 months. The plasma standards and patient samples were not stable 
after 5 hours of preparation, hence all the working standards and plasma specimens were 
analysed on the same day 
 
Matrix effect : It is the effect of the components of the matrix (plasma in this case ) on the 
ionization of isoniazid.This can effect various parameters like limit of detection, limit of 
quantification, accuracy and precision of various components.  It is measured using the LC-
MS/MS detector response of analyte in a matrix  with respect to standard solution. 
 
Matrix effect is given by a formula = peak area of isonazid from post precipitation spiked  
samples, divided by peak area of acqueous standards spiked with isoniazid 
 
Recovery for isoniazid from plasma following sample prepartion is given by  
peak area from preprecipitation plasma extracts, divided by peak area of same concentration 
of isoniazid ,spiked into blank specimens after precipitation . 
Both recovery and matrix effect was within the acceptable limit. 
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PHARMACOKINETIC RESULTS 
Overview of study population 
A total of 41 patients were recruited into the study.  Of these, two patients changed the 
regimen from a daily to an intermittent regimen, (after two weeks of initiating ATT) and 
they were excluded from the study.  Another patient was very sick in the intensive phase, 
and the fourth patient was lost to follow up.  A total of 37 patients completed the study. Out 
of these 37 patients, 26 were on an intermittent regimen and 11 on daily regimen.  The 
results were analysed using the statistical software R version 3.1.2. and Pmetrics Version 
1.3.2, which is a non-parametric modelling software (see section - on fundamentals of 
population modelling). 
Baseline characteristics 
The baseline demographic characteristics of the children included in the study are 
summarised in Table 6 and 7.  The study population was heterogeneous in terms of age and 
gender (Figure 17).  Only 23 % of the children on the intermittent regimen were adolescent 
as compared to 54 % of the children on the daily regimen. Though the WHO recommends 
Xpert PCR as first line investigation for all children, it is not done routinely in all patients.  
All of the data, apart from the PK data was analysed using non-parametric methods 
(Wilcoxon Rank Sum Test).and reported as median(IQR) The PK data is reported as a 
summary of the mean and standard deviation.\
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Figure 17   Gender Distribution and Pie chart for Age group 
 
 
Table 6   Summary of Baseline Demographic Charecteristics 
 
Parameter Intermittent Regimen Daily Regimen p value 
Number of Children 26 11 - 
Age (years) 4.75(2.9-11.4) 12.80 (6.9-14.2) 0.052 
Sex(M/F) 20/6 6/11 - 
Body  weight (kg) 14.82(11.3-24.6) 37.03(20.1-40.8) 0.008 
 
The nutritional status of children was assessed using the WHO Anthro and Anthro Plus 
Software for children less than 5 years and greater than 5 years respectively (131). The 
software calculated the Z scores based on height, weight, date of birth, date of visit, and 
presence or absence of oedema. There was also provision for adjustment in case the exact 
date of birth was unknown. For 3 children the exact date of birth was unknown and hence 
70%
30%
GENDER
MALE FEMALE
22%
24%
22%
32%
NO. OF CHILDREN  IN DIFFERENT 
AGE GROUPS
<3 >3 -  < 6 >6 - < 12 >12 - < 17
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the year of birth was used.  11% and 25% of the patients had thinness and severe thinness 
(assessed using Z scores for BMI). (see Appendix VI). 
 
Table 7 Baseline characteristics 
 
 
Note: Haemoglobin results were available for 35/37 patients and serum albumin for 32/37 patients. 
Pharmacokinetic results of isoniazid 
Comparing Intermittent and Daily ATT regimens 
The recommended Cmax and AUC0-24h for adequate bactericidal action of isoniazid is 3-6 
µg/mL and 10.52 mg.hr./L respectively (124). Of the 37 patients, the isoniazid 
concentrations were not measured for two patients due to a breakdown in the LC-MS/MS. 
The results between the two regimens are summarised in Table 11.  
 
 
Parameter Result Regimen 
Pulmonary 31/36 23/26 and 8/10 in intermittent versus daily 
Lymph node 5/36 3/26  and 2/10 
Prophylaxis 1/37 on daily regimen 
Bacteriologically confirmed 16/36 6/26 and 10/10 in intermittent versus daily 
Haemoglobin (g/dl) 11.3(10.63-12.38) Common for both the regimens 
Albumin (mg/dl) 3.7(3.5-4) Common for both the regimens 
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Table 8 Isoniazid Results Summary 
Parameter Intermittent Regimen 
(n=24) 
Daily Regimen 
(n=11) 
p value 
Dose per kg bodyweight 
(mg/kg) 
10.13 ( 8.14-11.5) 8.10  (7.35-9.3) 0.0051* 
Cmax (μg /mL) 6.82 ( 5.08-8.625) 6.86 (5.09-8.70) 0.942 
T max (hr) 1.0 (1-2) 1.0 (0.75-1.5) 0.6045 
AUC0-6h (mg.hr/L) 22.18 (13.5-28.3) 24.55(19.4-28.6) 0.8279 
C2 μg /mL (concentration 
at 2hrs) 
5.10 (3.5-6.7) 5.54 (4.4-5.5) 0.717 
C0 μg /mL (trough 
concentration) 
below the limit of 
detection (0.00-0.03) 
0.15 (0.035-0.22) 0.00093* 
C6 μg/mL (concentration 
at 6hrs) 
2.010 (1.21-2.85) 2.18 (1.07-2.87) 0.78 
No of children with 
Cmax >3 μg /mL 
21/23 11/11 - 
 
Note: all values are in median (IQR-interquartile range), n= number of patients. 
Limit of detection of isoniazid-0.01 μg /mL
 
 
As evident from the table 8, the dose per kg body weight was significantly higher in children 
receiving intermittent regimen versus daily regimen (p=0.0051). The trough concentration 
differed significantly between the two regimens.  All 11 patients in the daily regimen, except 
one, had a trough concentration greater than 0.05µg/mL.  In the intermittent regimen, 20 
out of 26 patients had a trough concentration below the limit of detection (0.01 µg/mL) and 
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remaining 6 out of 26 patients had a measurable trough concentration greater than 0.01 
µg/mL.  This can be attributed to the thrice weekly regimen and. short half-life of isoniazid. 
 
From the total data, two patients had a Cmax that was less than the recommended 3µg/mL. 
Both these patients were in the intermittent regimen group. 33% of the patients from the 
intermittent and 36% of the patients from the daily group had Cmax values within the 
therapeutic range (3-6 μg /mL). 54% of the patients from intermittent and 64% of the 
patients form daily had Cmax above the therapeutic range (see Figure 18).  
 
 
 
 
There is a strong correlation between Cmax and AUC in both the ATT regimens (r =0.92 and 
0.862 in intermittent and daily regimens respectively).  There is also a strong correlation 
between the concentration at 2 hours and AUC0-6h (r =0.92, and 0.93 for intermittent and 
daily respectively) in both the regimens.  All the patients (n=34) except one had an AUC0-
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Figure 18 Distribution of isoniazid Cmax in total population 
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24h greater than 10.58. mg.hr/L.  There was no significant difference in Cmax and AUC0-6h 
between the two regimens (see Figure 19). 
 
The time for reaching Cmax (Tmax) was 1 to 1.5 hours for 55% of the patients, 2 hours for 20 
% of the patients and 0.5 hour for 17 % of the patients. The results in relation with isoniazid 
dose and Cmax is shown below in Table 9. 
 
Table 9 Results in correlation with isoniazid dose as per RNTCP 2012. 
Parameter Cmax 3-6  µg/mL Cmax > 6µg/mL. 
% of children 34% 59% 
% reduction in dose 
administered compared 
to RNTCP 2012 
40% 31% 
AUC0-6h > 10.53 
mg.hr/L. 
All patients All patients 
Median AUC0-6h mg.hr/L 16.34 mg.h/L 27.81 mg.h/L 
(p= 0.000373) 
 
The AUC0-6h in both intermittent and daily regimens; concentration at different points are 
shown in Figure 19,20,21 and 22. 
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Figure 19 AUC 0-6h  in intermittent versus daily regimen 
    
 
Figure 20    Plot showing isoniazid concentrations at different time points 
                     for total study population 
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Figure 21 Plasma time concentration profiles in intermittent 
regimen 
Figure 22 Plasma time concentration profiles in daily  regimen 
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Summarised Results (common for both the regimens) 
The interindividual variability was calculated using coefficient of variation (CV %). The 
equation is  as follows 𝐶𝑉 = (
𝑆𝐷
𝑀𝐸𝐴𝑁
) ∗ 100 
Interpatient variability for dose normalized AUC was 34% and for dose normalised Cmax 
was 40.4 %, in the total study population. 
 
Effect of Age:  There were 7 patients below 3 years of age and 28 above three years. The 
results of the Wilcox Rank Sum test, showed a significant difference in AUC0-6h between 
children less than 3 years (median AUC0-6 was 20.280 mg.hr /L) and children greater than 
3 years (median AUC0-6 24.10 mg.hr/L), p value =0.05.  The median Cmax µg/mL was 5.7 
versus 7.11, (p=0.19), in children less than 3 years and greater than 3 years respectively  
 
Effect of Albumin and Haemoglobin  
There was a moderate correlation between serum albumin and isoniazid AUC0-6h (r = -0.612, 
p = 0.0008). There was no correlation between albumin and Cmax (r = -0.40, p =0.03). 
There was no correlation between haemoglobin and AUC0-6h or haemoglobin and Cmax (r= 
-0.10and r=-0.4; p value of 0.78 and 0.61 respectively). 
 
Phenotypic acetylator status: Three from the intermittent regimen and two from the daily 
regimen were fast acetylators.  The AUC 0-24h was lower in fast acetylators compared to 
slow (20.44 vs 34. 286 mg.h/L; p value 0.0291). 
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Effect of Dose: 
There is a moderate correlation between the AUC0-6h (mg.hr./L) and the dose per kilogram 
bodyweight (r =0.54, p=0.00009). 
The Cmax(µg/mL) also correlated with dose per kilogram bodyweight (r=0.40 and p=0.01). 
 
Effect of BMI: 
There was no/poor correlation between BMI and AUC (r value=-0.04, p=0.7) or BMI and 
Cmax (r= -0.11, p=0.5). There were 7 patients with BMI less than 13.5 and 28 patients with 
BMI greater than 13.5. The median AUC0-6h mg.hr/L (22.18 versus 24.55, p value =0.09) 
and median Cmax µg/mL (5.68 versus 7.11, p value=0.1) in patients with BMI lesser than 
13.5 versus those with BMI greater than 13.5 respectively, did not show a difference that 
was statistically significant. 
 
Effect of Gender: Gender had no significant effect on AUC or Cmax. The median AUC was 
22.17 mg.hr/L in females and 22.90 mg.hr/L in males and was not different (p =0.77) The 
median Cmax (µg/mL) was 5.680 in females and 6.910 in males and was not different (p-
0.31). 
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Pharmacokinetic results of rifampicin: 
Comparing Intermittent versus Daily ATT Regimens 
The therapeutic range for Cmax of rifampicin is 8-24 μg/mL (124).  The results are 
summarised in Table 10. 
 
Table 10: Rifampicin results summary 
Parameter 
 
Intermittent Regimen 
(n=26) 
Daily Regimen 
(n=11) 
p value 
Dose per kg 
bodyweight 
10.18(8.27-11.360) 10.77(9.27-11.66) 0.4 
Cmax (μg /mL) 6.315(3.872-7.422) 5.590(2.950-7.350) 0.7 
T max (hr) 2(1.00 -2.50) 2 (1.5-2.25) 0.67 
AUC0-6h (mg.hr/L) 16.870(10.4-21.760) 16.50(9.011-21.230) 0.93 
C2μg/mL 
(concentration at 
2hrs) 
4.34(3.01-5.8) 4.43(2.0-5.68) 1 
C0 μg/mL (trough 
concentration) 
Below the limit of 
detection 
0.01 0.03 
C6 μg/mL 
(concentration at 6 
hrs) 
1.01 (0.63-2.32) 1.68(0.71-2.8) 0.42 
Note: all values are reported as median (interquartile range).
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The median dose per kg body weight was not different between the two regimens (p=0.4). 
Four out of 26 patients on the intermittent ATT regimen had a Cmax (µg/mL) concentration 
within the recommended range of 8-24 µg/mL.  Similarly, 2 out of 11 patients from the 
daily regimen had a Cmax (µg/mL) concentration within this recommended range.  A total 
of 84.6% and 81.8% of patients in the intermittent and daily regimen groups had a Cmax 
below this recommended range respectively. 
 
Fifteen out of 26 and 4 of 11 patients had a Cmax between 4-8µg/mL in the intermittent and 
daily regimen respectively. The rifampicin Cmax less than 4µg/mL is considered to be very 
low concentration.  Seven out of 26 and 4 out of 11patients had a Cmax less than 4 µg/mL in 
the intermittent and daily regimen respectively(132).  In all 37 patients, no patient had a 
Cmax greater than 12.8 µg/mL.  
 
Figure 23  Rifampicin Cmax distribution in the total study population 
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In our study, 30 % of patients had a Cmax at 2 hrs.  The Tmax was between 0.5 to 1.5hr for 40 
% of the patients and 15 % patients had a Tmax after 2 hours (one at 6 hrs). 
The trough concentration for rifampicin was below the limit of detection (0.01) in all the 
patients on the intermittent regimen. In the daily regimen 2 out of 11 patients, had a 
measurable trough concentration (maximum of 0.08) but the remaining 9 patients had a 
trough concentration below the limit of detection. (0.01) 
In the intermittent and daily regimen groups 29 % and 27% of the patients respectively had 
an AUC 0-24h less than 13 mg.hr/L.  
 
Summary of the Results (common for both the regimens) 
AUC0-6h strongly correlated with Cmax in both the regimens (r =0.89 and 0.98 for intermittent 
and daily regimen respectively). There was a good correlation between concentration at 2 
hours and AUC0-6h (r=0.90 and 0.91 for intermittent and daily respectively).  The 
interindividual variability (as %CV) for rifampicin AUC0-6h and Cmax, normalized to dose, 
was 55% and 59% respectively. 
The rifampicin AUC in both the regimens as well as concentrations at different time points 
are summarised in Figure 24,25,26 and 27
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Figure 24 Rifampicin AUC in intermittent versus daily regimen 
 
Figure 25 Rifampicin concentrations at different time points 
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Figure 26 Plasma concentration time profile of rifampicin in intermittent regimen 
 
 
Figure 27 Plasma concentration time profile of rifampicin in daily regimen 
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Effect of Age: 
The median AUC0-6h mg.hr./L was 12.45 versus 17.86 in patients less than 3 years and 
greater than 3 years respectively. This difference was not statistically significant (p=0.36). 
 
Effect of Gender: 
The median AUC mg.hr/L was 13.57 versus 16.87 in females versus males. There was no 
statistically significant difference in drug exposure based on gender (p=0.563). 
 
Effect of Dose: 
There was no significant correlation between dose per kg bodyweight and AUC (r=0.19, 
p=0.37) or between dose per kg body weight and Cmax (r=0.037, p=0.6). 
 
Effect of Weight: There was a good correlation between weight on the day of study and 
AUC0-6 in the daily regimen patients (r=0.65, p=0.030).  However, no such correlation was 
found in patients on intermittent regimen (r=0.03, p=0.868). 
 
Effect of Haemoglobin and Albumin: 
There was a moderate correlation between Cmax and haemoglobin (r=0.51, p =0.0076).  
There was also a similar correlation between haemoglobin and AUC0-6h mg.hr/L (r=0.52, 
p=0.0059).  The correlation between albumin and Cmax was – 0.61 (p=0.008).  However, no 
correlation was found between albumin and AUC0-6h. (r=0.25, p=0.5). 
 
Effect of BMI: 
There was no correlation between BMI and AUC (r value=-0.06, p=0.72) or BMI and Cmax 
(r= -0.11, p=0.5).  
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Treatment outcome 
Three children were smear positive in the intermittent regimen group, at the start of therapy. 
Out of them, two patients did not respond at the end of intensive phase. Both these patients 
had a Cmax rifampicin concentration less than 8µg/mL (one patient had a concentration of 
less than 4µg/mL).  However, the isoniazid Cmax was greater than 6µg/mL for both these 
patients.  The third patient, did not gain weight at the end of the intensive phase but was 
smear negative and considered to be a responder. 
Since many patients on intermittent regimen were smear negative at the time of initiation, 
only clinical parameters were used for defining response (which include: resolution of fever 
and or cough, weight gain, improved appetite, reduction of lymph node size).  All these 
patients were clinically asymptomatic at the end of intensive phase and considered as 
responders. The weight gain over the baseline was 6.0 %. 
 
Treatment outcome of children on daily regimen 
All the patients from daily regimen were bacteriologically confirmed for tuberculosis using 
various investigations like sputum smear, culture, biopsy or Xpert /PCR. 
Amongst these, only 2 children were sputum smear positive at initiation.  Both were smear 
negative at the end of intensive phase. Out of these 2 patients, one patient did not gain 
weight at the end of the intensive phase but was smear negative and considered to be a 
responder.  Both these patients had a Cmax for isoniazid >3 µg/mL, and Cmax for rifampicin 
between 4-8 µg/mL. 
For the remaining patients a repeat culture or biopsy or Xpert was not done except for one 
patient for whom repeat Xpert at the end of 2 months was positive who was considered as 
a non-responder.  
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The average weight gain in children on daily regimen was 7.6 % (excluding the one patient 
who did not gain weight). 
To conclude ,9/10 patients on daily regimen and 24/26 from intermittent regimen were 
considered as responders at the end of intensive phase. 
One patient on daily regimen was on prophylaxis, was considered as responder based on 
clinical examination. 
Please see data chart on the following page. 
However, it has to be noted that there are other non-drug related factors like initial bacillary 
load, miliary tuberculosis, presence of cavitation etc., which also effect the response rate 
(133,134).  Similarly, other concomitant administered drugs like pyrazinamide and 
ethambutol also contribute to the final outcome. 
 
 
 
 
 
 
 
 
 
 
 
 
NUMBER Regimen Basis of diaclinical features include loss of appetite and feverwith or withS/O TB At the end of the intensive phase
History of c Clinical featureXpert PCR AFB smear Culture Biopsy Radiologica Clinical featXpert Smear weight gain(Treatment outcome
1 intermittent no yes NA negative no growth NA yes resolved NA negative 1.02 responder
2 intermittent yes yes NA negative NA NA yes resolved NA NA 0.5 responder
3 intermittent yes yes NA negative NA yes resolved NA negative 0.93 responder
4 intermittent yes yes NA negative NA NA yes resolved NA NA 0.3 responder
5 intermittent yes yes NA negative NA NA yes resolved NA NA 0.44 responder
6 intermittent yes yes NA negative NA NA yes resolved NA NA 2.57 responder
7 intermittent yes yes NA negative NA NA yes resolved NA NA 0.42 responder
8 intermittent no yes NA negative no growth NA yes resolved NA NA 0.5 responder
9 intermittent no yes NA negative no growth NA yes resolved NA NA 1.02 responder
10 intermittent yes yes NA negative no growth NA yes resolved NA NA 0.8 responder
11 intermittent no yes NA negative NA NA yes resolved NA NA -0.4 responder
12 intermittent yes yes negative positive NA NA yes partly resolvNA positive 0.6 not a responder
13 intermittent yes yes NA negative NA NA yes resolved NA NA 0.5 responder
14 intermittent no yes NA negative NA NA yes resolved NA NA 0.8 responder
15 intermittent yes yes NA negative NA NA yes resolved NA NA 0.7 responder
16 intermittent no yes NA NA NA yes lymphnoyes partly resolvNA negative 2 responder
17 intermittent yes yes NA positive NA na yes resolved NA negative 0.06 responder
18 intermittent no yes NA positive NA NA yes partly reslovNA positive 3.7 not a responder
19 intermittent no yes NA negative NA NA yes resolved NA NA 0.96 responder
20 intermittent yes yes+lymphnod NA negative NA yes lymphnoyes resolving lymNA NA 0.8 responder
21 intermittent yes yes + lymphno NA negative NA yes  lymphnyes resolving lymNA NA 0.7 responder
22 intermittent no yes NA negative NA na yes resolved NA NA 0.9 responder
23 intermittent no yes NA negative NA NA yes resolved NA NA 0.3 responder
24 intermittent yes yes NA negative NA NA yes resolved NA NA 0.5 responder
25 intermittent yes yes NA negative NA NA yes resolved NA NA 1.2 responder
26 intermittent yes yes NA negative no growth NA yes resolved NA NA 0.3 responder
NUMBER Regimen Basis of diaclinical features include loss of appetite and feverwith or withS/O TB At the end of the intensive phase
History of c Clinical featureXpert PCR AFB smear Culture Biopsy Radiologica Clinical featXpert Smear weight gain(Treatment outcome
27 daily no yes positive negative negative NA positive resolved negative negative 3.5 responder
28 daily no yes NA positive positive NA yes partially resoNA negative -1.4  responder
29 daily no yes + lymphno NA NA no growth lymphnode pNA resolved,reduced lymph node size 3.1 responder
30 daily yes yes + lymphno positive no AFB seemno growth NA yes resolved NA negative 2.5 responder
31 daily no yes positive negative NA NA yes resolved NA negative 1.58 responder
32 daily no yes positive negative NA yes resolved positive negative 1.8 responder
33 daily no yes NA NA no growth lymphnode pNA yes ,LN reduNA NA 0.85 responder
34 daily no yes NA NA no growth pleural biopsy positive yes NA NA 1.36 responder
35 daily yes yes NA NA NA pleural biop yes yes NA NA 1.34 responder
36 daily no yes+lymphnod positive NA no growth NA yes partly resolvpositive negative 3.5 not a responder
Page-87
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RESULTS FOR POPULATION MODELLING –  
 Isoniazid Model using Pmetrics: 
A non-parametric two-compartment oral absorption model was developed and validated 
using Pmetrics® for R (see Figure 28).  As discussed previously, the model file used has 
the following inputs: 
Ke = elimination rate constant, VD = volume of distribution, Ka=absorption rate constant, 
KCP: rate constant from central to peripheral compartment and KPC: rate constant from 
peripheral to central compartment. 
The main covariates were: Age, Gender, Weight, Height and BMI.  The estimated 
parameters as developed from the model are summarised in Table 11. 
 
Table 11 Population parameters isoniazid 
 
 
 
 
Population 
Pharmacokinetic 
Parameter 
Mean Standard 
Deviation 
CV Median 
Ke 0.491 0.152 30.83 0.439 
V 15.025 5.658 37.65 14.628 
Ka 2.472 2.932 118 1.779 
KCP 1.828 2.528 138 0.466 
KCP 7.032 3.636 51.6 9.998 
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Figure 28 Isoniazid mode for individual and population pedictions l 
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As evident from the figure, the individual model had a coefficient of determination R2 = 
0.922.  The model had a bias of  -0.034 and an imprecision of 0.688. 
 
The marginal density plots of the individual primary variables in the model are in Appendix. 
V. 
The population predicted model had a correlation of 0.44 with a bias and an imprecision of 
1.65 and 11.2 respectively. Both imprecision and bias were within the acceptable limit. 
Rifampicin model using Pmetrics 
A non-parametric one-compartment oral absorption model was developed and validated 
using Pmetrics ® for R. As discussed previously, the model file used has the following 
inputs: 
Ke =elimination rate constant, VD = volume of distribution, Ka=absorption rate constant, 
KCP: rate constant from central to peripheral compartment, KPC: rate constant from 
peripheral to central compartment.  The main covariates were: Age, Gender, Weight, 
Height, BMI and time lag for absorption.  The estimated parameters as developed from the 
model are mean (SD) are Ke 0.6162(0.57) hr-1, VD of 35.7 (4.4) litres, T lag=0.98(0.85) hr. 
The developed model for individual and population prediction had an R2, imprecision, bias 
of 0.98 ,0.88 and -0.175, versus 0.243,52.6 and 1.55 respectively. (see Figure 29) 
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Figure 29 –Rifampicin model for individual and population predictions 
 
 
  
  
DISCUSSION 
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DISCUSSION 
 
Children are considered as a vulnerable population and hence are often excluded from 
pharmacokinetic studies. Most pharmacokinetic studies in children with tuberculosis have 
been done within the past 15 years in various parts of the world including India.  This study 
is one of the few studies with intensive sampling over 6 hours (8 time points) in children on 
ATT comparing daily and intermittent regimens from Indian paediatric population. 
 
Pharmacokinetic studies in children have shown that children need a higher dose per kg of 
isoniazid and rifampicin when compared to adults,  to achieve the same plasma 
concentration (124,125,135).  Thee et al in 2009 studied the pharmacokinetics of rifampicin 
when co-administered with ethambutol in children and suggested that a rifampicin dose of 
more than 10mg/kg (which is the current dose used ) was more appropriate (136).  They 
also suggested that dosing based on BSA (body surface area) rather than bodyweight may 
be more adequate.  
 
Since low plasma concentrations are closely related to delayed therapeutic response, 
prolonged infectiousness, relapse or emergence of drug resistance, the WHO revised the 
ATT dosage in 2010 for children (108). Based on the latest WHO guidelines for the 
treatment of childhood tuberculosis, the RNTCP, in 2012, revised the ATT drugs doses. 
(111).  However, the new paediatric weight band boxes are not yet implemented. 
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The revised RNTCP (2012) doses with new bands (summarised in Table 1) are higher with 
narrow weight bands, so the problem of overdosing or underdosing, for children on the 
extremes of the weight band is reduced. 
 
ISONIAZID 
Isoniazid's bactericidal action mainly depends on AUC0-24h/ MIC ratio and the emergence 
of drug resistance is related to both AUC/MIC and Cmax/MIC (137).  The AUC0-24h of 
10.52mg.hr./L is associated with 90% of maximal killing of metabolically active bacilli 
present in the sputum for the initial 2 days (ED50) (138). 
 
In our study, there was no significant difference for isoniazid with respect to Cmax and AUC0-
6h between the two regimens.  It is interesting to note that the patients on a daily regimen 
were treated with a significantly lower dose of isoniazid compared to the intermittent group 
(median dose of 8.1 versus 10.13 mg/kg respectively). The comparable exposure in the daily 
group in spite of the lesser dosing could be attributed to many factors; one being the 
measurable trough concentration in the daily group leading to a cumulative effect on AUC, 
and more number of adolescent patients in the daily group. It is to be noted that even though 
there is similar AUC0-24h in both the groups, the daily group will receive this exposure for 
all seven days, whereas the intermittent group will only receive this exposure thrice a week. 
The influence of this on the clinical outcome in terms of relapse, would require a long term 
follow up (~2 yrs.) of our study population. 
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In our study population, only 2 patients (5.7% of total patients) had an isoniazid Cmax of less 
than 3 µg/mL, and both these patients were dosed at 80 % less than the current 
recommended dose (RNTCP current recommendation 2012). But the AUC0-24h was less 
than 10.53 mg.hr/L in only one of these patients. 
 
In spite of 83% of total number of patients receiving lower doses from those that are now 
recommended (RNTCP 2012), only 2 patients (5.7%) did not achieve the Cmax target 
concentrations of 3-6µg/mL.  However, 34% of patients had Cmax within 3-6 µg/mL and 
59% had Cmax above 6 µg/mL.  
 
In our study, the median Tmax of isoniazid was at 1 hour in both the regimens. This finding 
was similar to the finding by Schaaf et al 2005 where the median Tmax was at 0.75 hr. A  
Tmax at 1 hour was also reported from an Indian study in children with tuberculosis by 
Aparna Mukherjee et al (139). 
 
With respect to Cmax and AUC, our results were similar to those reported by Ramachandran 
et al in 2013 (125), in a paediatric population.  The median Cmax and AUC were 6.2 µg/mL 
and 24.3 mg.hr/L respectively in their study population versus 6.84 µg/mL and 22.54 
mg.hr/L in our study.  
 
Ramachandran et al also reported a significantly lower AUC0-8h in children <3 yrs (median 
14. 9mg.h/L), compared to those above 3 years (median 26.7 mg.h/L). In our population, 
median AUC0-6h was 20.28 mg.hr /L versus 24.10 mg.hr/L in children less than 3years and 
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greater than 3 years respectively.  However, this difference based on age was not reflected 
in the Cmax values.  In our study, the smaller sample size of children <3 yrs (n=7) may be 
inadequate to show a significant difference in drug concentration compared to the >3 years’ 
group. 
 
The pharmacokinetic parameters for our patients obtained from the model were the mean 
(SD) of first order elimination rate constant K (0.26 ± 0.09 / h), clearance (8.27± 6.1 L/h), 
volume of distribution (39.51± 28.6 L) and t1/2 (3.0 ± 1.07 hrs).  These results were similar 
to those reported by GM Rangari et al in  Indian study patients (140).  They found an 
elimination rate constant of 0.16±0.01 /h, clearance 7.1±0.8 L/h, the volume of distribution 
44.05±5.3 L and a half-life of INH 4.3±0.4 h. 
RIFAMPICIN 
Rifampicin’s bactericidal action, like isoniazid, is mainly related to AUC/MIC. The 
resistance suppression action is linked to Cmax/MIC and not to the total time duration above 
MIC.  Hence, adequate Cmax and exposure in terms of AUC is essential for its bactericidal 
and rapid sterilizing action.  An AUC0-24h of less than 13mg.hr/L is a predictor of poor long-
term outcome (141). 
 
There were total of 37 patients (intermittent + daily), and for two of them (taking the 
intermittent dosing regimen) all the time points were not available and hence, the AUC was 
not calculated for them. 
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Of the 37 patients, 83% had rifampicin Cmax lower than the therapeutic range (8-24µg/mL).  
This is in close agreement with the study reported by Ramachandran et al, where the authors 
stated that 90% of all children treated on similar doses by intermittent regimen, had sub-
therapeutic rifampicin concentrations for Cmax (125).  In addition, LM Verhagen et al also 
reported that 77% of children on daily regimen had rifampicin Cmax <8 ug/mL (124). 
 
Out of all 37 patients, 62% were dosed less than the RNTCP (2012) recommendation.  
Doses in mg/kg do not correlate well with rifampicin exposure because only 2 children out 
of 6 who achieved the recommended range were dosed adequately. Similarly, there were 11 
children who had values in the very low category of < 4µg/mL and of these 5 children were 
dosed correctly.  There were 19 children who had values in the low category of >4 and < 
8µg/mL and of these 4 children were dosed correctly.  
 
This finding of dose not correlating with the Cmax is similar to a study in Indian patients by 
Aparna Mukherjee et al where they found that the majority of the patients did not achieve 
adequate Cmax, in spite of higher doses used in their study on daily regimen patients. 
 
All the patients who had an adequate rifampicin Cmax (6 out of 37) had a median (IQR) AUC 
0-24 of 31.32 mg.hr/L (26.50 -40.32) whereas in the majority patients, who had an inadequate 
Cmax (n=31), the median (IQR) AUC0-24h was 13.60 (8.57-18.43).  The difference in AUC 
was statistically significant in the above two groups (p=0.0000014). 
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The AUC0-24h was greater than 13mg.hr/L in 63% of patients whilst the remaining 37% had 
AUC0-24h <13 mg.h/L.  It should be noted that all the patients with a low AUC had a Cmax 
< 8 µg/mL. 
 
From this study, we recommend the use of therapeutic drug monitoring for rifampicin, in 
particular, for patients who are not responding to therapy.  In the event of a low Cmax, an 
increase in the dose must be considered.  This is especially true if the concentration is less 
than 4 µg/mL. 
 
From the model we developed, the mean (SD) of first order elimination rate constant K 
was 0.45 ± 0.29 hr, clearance was (L./hr) 20.63 ± 36.6, volume of distribution (L) 81.88 ± 
117.9 and half-life of 2.07 ± 1.29 hrs. 
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CONCLUSIONS 
 
1. A total of 83 % of the patients were under-dosed for isoniazid when compared to the 
latest RNTCP 2012 recommendations, which are not yet implemented. 
 
2. With the dose used in this study, 34 % of the patients had an isoniazid Cmax within 
the recommended range (3-6µg/mL) and 59 % of the patients had a Cmax > 6 µg/mL. 
This would suggest that the dosing based on RNTCP (2004) guidelines, were 
adequate, in terms of the recommended Cmax therapeutic range.  Further studies may 
be required to confirm the clinical significance of this finding.  
 
3. The mean dose of isoniazid in the daily regimen was lower than the intermittent 
group.  However, the exposure in terms of Cmax and AUC was similar for isoniazid 
between the intermittent and daily regimens.  The only difference being the seven-
day exposure for patients on daily compared to the same exposure for only three 
days for patients on intermittent therapy.  
 
4.  Out of all the study population, 62% of the patients were under-dosed for rifampicin 
when compared to RNTCP 2012 guidelines.  
 
5. Only 17% of the patients had Cmax for rifampicin, within the reference range of 8-
24µg/mL.  With the doses used in this study, 83 % of patients had Cmax <8 µg/mL, 
and 31% of the patients had a very low Cmax for rifampicin of <v4µg/mL.  This 
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indicates that the newer RNTCP guidelines, which recommend higher doses, should 
be implemented at the earliest for rifampicin.   
 
6. The majority of patients had a Cmax for both isoniazid and rifampicin before 2 hours 
and therefore pharmacokinetic studies and TDM in children for isoniazid and 
rifampicin should include earlier time points to capture the Cmax accurately. 
 
7. The dose of rifampicin does not appear to have a correlation with the exposure.  Also 
rifampicin has a high inter-individual variability (% CV of 54 % for AUC and 59% 
for Cmax).  Thereby we recommend the use of TDM for patients on rifampicin 
(especially for patients who do not respond adequately or respond slowly) 
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LIMITATIONS 
The study included two most important first line drugs namely isoniazid and rifampicin, 
excluding pyrazinamide and ethambutol. Adequacy of doses and thereby serum 
concentration of ethambutol and pyrazinamide will also have a role in assessing the 
clinical outcome.  Other forms such as tuberculous meningitis, which would constitute 
sicker patients with higher morbidity and mortality, were excluded.  
 
Since the maximum amount of blood that can be drawn from a child in a day is limited 
(142), the later time point specimens were not collected.  If done, it would have resulted 
in more accurate predictions for AUC0-24h. 
 
Diagnosis of tuberculosis in children is primarily a clinical diagnosis.  Therefore, the 
clinical outcome was only based on clinical improvement, in patients who were smear 
negative.  Since this is an ongoing study, the outcome of the treatment could not be 
assessed in all the patients.  
 
Although none of the patients presented with signs of drug induced hepatotoxicity, we 
did not voluntarily do liver function tests to confirm. 
 
We were unable to recruit children younger than three years (who are more susceptible 
to lower drug concentrations and higher mortality) in the daily regimen.
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FUTURE SCOPE 
 
1. The possibility of decreased drug concentrations appears to be more in the lower age 
groups. This highlights the need to target this age group (<3 yrs.) for future 
pharmacokinetic studies. 
 
2.  Pharmacokinetic studies for ATT drugs should be planned as long-term studies, 
with prolonged follow up. This would help to assess the incidence of relapse and 
thereby assess possible correlation between drug concentrations and clinical 
outcome.  Such studies may need sequential PK monitoring throughout the period 
of treatment (at 1 month, 2 months, 3 months and towards end of treatment) in 
children. 
 
3. RNTCP (2012) guidelines recommend higher doses compared to the previous. The 
boxes with these new dosages are yet to be implemented. It would be worthwhile 
comparing the pharmacokinetics, short term and long term clinical outcome with the 
older doses (as used in this study) and the newer doses (to be implemented in future) 
in children. 
 
4. Pharmacokinetic monitoring in children with high morbidity and mortality as in HIV 
positive patients and for tuberculous meningitis. Monitoring of drug concentration 
should also include ethambutol and pyrazinamide concentrations 
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5. More evidence has to be added to the importance of TDM, in particular to rifampicin 
monitoring, especially for non-responders, at one month.  So thereby doses can be 
increased as necessary. 
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Annexure III Information Sheet, Consent and Assent Forms 
INFORMATION SHEET 
 
Study Title: Determination of pharmacokinetics of isoniazid and rifampicin under daily 
and intermittent anti-Tubercular (ATT) regimen, in children with tuberculosis. – A pilot 
study.  
 
1) What is this study about?  
Your child has a disease called as Tuberculosis. Tuberculosis is an infection caused 
by bacteria. It is a treatable condition, provided all the medicines are taken regularly for 
adequate duration (usually 6 months). In the treatment of tuberculosis 4 drugs are used in 
combination and they can be given either daily or thrice weekly. The treatment plan will be 
decided by the clinician.  
 
In our study we would like to know the behavior of two most important drugs used 
in tuberculosis, namely isoniazid and rifampicin (by measuring their concentrations in 
blood at multiple time points) in your child’s body. Though such studies were done in 
adults, there are very few studies involving children. Children differ from adults in many 
aspects. So it is important to know details about drug concentrations in children. If the drug 
levels are not adequate in blood, then the treatment may not be completely effective 
(response will be slow or no response at all). Also because treatment is given on daily 
versus intermittent basis, we would like to see whether there is a difference in the 
concentrations achieved in both groups. To study that, multiple blood samples will be 
collected (8 times, 2mL each) over a period of 6 hrs.  
 
2) What I have to do to take part in this study?  
After your informed consent, you will be enrolled into this study.  
Generally, you will be asked to visit the doctor at the end of the 2nd month to 
ascertain your child’s health. The study will also be carried out around the same time. One 
day before the study we will make a telephone call to you and explain the procedure, 
instructions for next day’s study. On the day of sampling, you will have to report at 7.45 am 
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and have to stay at the venue at least for 6 hours. A venous cannula will be inserted to your 
child’s arm. From this venous cannula, blood samples will be drawn over a period of 6 hrs. 
If your child is not comfortable during the process of the study you can just inform us and 
withdraw from the study.  
 
3) Are there any other tests?  
No.  There are no other tests apart from the above.  
 
4) Will I have to pay anything?  
No. You do not have to pay anything.  Lunch will be provided on the day of the 
study and a travel allowance of 50 rupees will be given from our side.  
 
5) Is it compulsory to take part in the study? 
No.  Participation is purely voluntary and based on your decision. Your child’s 
treatment will not be affected in any way even if you do not participate.  You can withdraw 
from the study at any time by informing us. 
 
6) How will this study benefit me and others?  
The study results will be conveyed to your child’s doctor.  Depending on that they 
will assess the need for dosage change.  Apart from that the results will be useful in future 
for choosing different regimens and deciding appropriate doses in childhood tuberculosis.  
 
7) Will my child’s confidentiality be maintained?  
Yes. We will maintain absolute confidentiality. Nowhere during/after the study will 
your child’s identity be revealed.  
 
8) Can I withdraw in between if I do not wish to continue my participation?  
Yes. You can withdraw your participation at any point of time by informing us. 
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Contact number and E-mail address are given below:  
1. Dr. Winsley Rose  
Contact number: 04162284207  
Email: winsleyrose@cmcvellore.ac.in   
2.  Dr. Jaya  
Mobile phone 09790210720  
Email:patwarijaya@gmail.com
 
 
INFORMED CONSENT 
 
Study Title: Determination of pharmacokinetics of isoniazid and rifampicin in both daily 
and intermittent anti-Tubercular (ATT) regimen, in children with tuberculosis – A pilot 
study. 
 
If you have volunteered to participate in this study please complete this form and sign it.  
If you have any doubts, please feel free to ask questions and get them clarified. 
 
I Mr/Ms/Mrs have read the information sheet provided to me which describes 
about this study and its importance.  I understood the details and had enough opportunity 
to discuss it with the research staff and clarify my doubts.  I understand that I have the 
right to deny participation in this study and also know that denial does not affect the 
process of medical care to my child. 
 
 I was given enough time to think about it and to decide if I am willing to allow my child 
to participate { } 
 
 I am willing to allow my child to participate in the study { }  
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I give consent for my child’s blood samples to be drawn (8 samples, 2mL each) and used 
for research purpose { } 
 
I understand if the results are published or presented at scientific meetings, my child’s 
identity will not be disclosed, without my written consent { } 
 
I give permission for the use of any results that arise from this study for scientific 
purpose(s) { } 
 
I understand that this test is not a diagnostic test and is only for research purpose { }  
 
I understand that I will not have any direct benefit now from the study but the outcome of 
the study will be of help to future patients { }  
 
I understand that I can withdraw from this study at any time. { }  
 
I have signed this consent voluntarily and whole-heartedly and out of my free will, 
without any pressure from anyone. { }  
 
Name ________________________________ 
Signature / Thumb print __________________________ Date: _____ 
 Name of Witness __________________________________________ 
Signature / Thumb print___________________________ Date_______ 
Name and signature of the person who has taken the informed consent: __________ 
 
 
Page | 9  
 
Page | 10  
 
 
Page | 11  
 
Appendix I Case Record Form  used for this study               
Study Number:                               Age:                       Sex:     
Date of first visit for present illness:                             
Date of diagnosis:                              Date of starting ATT:                            
Weight:          kg                              Height:       cm                      BSA: 
Serum ALT:                                       Haemoglobin:                   Serum Albumin:    
Diagnosis:  pulmonary TB / lymph node TB / prophylaxsisTB 
Clinical findings at the time of diagnosis: 
Fever: duration in days_____________ 
Cough: present / absent.  If present, durations in _________days 
Lymph nodes:  palpable / not palpable. If palpable: size____ cm 
Weight loss: yes / no. If yes, documented / not documented.  
If documented, loss in kg___ over past___ months  
Sputum / gastric Aspirate:       AFB smear: positive / negative  
                                                 AFB smear: positive / negative  
                                                 AFB smear: positive / negative 
AFB culture result: 
Lymph node biopsy:  done / not done 
Biopsy AFB smear / culture  
TB PCR site: ____________ positive / negative 
Radiological findings:        TST: positive / negative               H/O contact with TB: yes/ No            
Treatment regimen: Daily (1)   /    Intermittent (2) 
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DAY OF STUDY  
Date of specimen collection: 
Clinical Status Monitoring:         Resolution of Clinical Symptoms yes /No  
Weight   ____Kg             Height -------------Cm 
Lymph Nodes:  Palpable / Not Palpable. If Palpable: Size____ cm 
Weight Gain = ____Kg 
Dose / Body Weight on the day of Specimen collection. 
Timing of Blood Specimen Collection: 
Specimen 
hr) 
Trough 0.5hr 1.0hr 1.5hr 2hr 2.5hr 4hr 6hr 
Time          
 
Plasma isoniazid and rifampicin concentrations 
 
        
AUC0- 6 hrs isoniazid:                   AUC0- 6 hrs rifampicin: 
 
 
Time points 
Of sample 
collection 
Trough 
 
0.5hr 
 
1.0hr 
 
1.5hr 
 
2hr 
 
2.5hr 
 
4hr 
 
6hr 
 
Concentration 
(µg/dL) of INH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concentration  of 
rifampicin (µg/dL 
) 
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Appendix II- Data for rifampicin validation 
 Five different Extraction of concentration 5µg/mL 
Actual 
Concentration(µg/mL) 
 IS  
RT(min)Area 
  rifampicin 
 RT(min)       
Area 
Ratio Measured(µg/mL) 
5 3.886 265617 13.373 112164 0.422 5.14 
5 3.89 263087 13.39 111626 0.424 5.14 
5 3.88 262858 13.395 112055 0.426 5.27 
5 3.88 255585 13.379 110115 0.431 5.27 
5 3.952 256217 13.368 110842 0.433 5.27 
 
 
Table 1  Inter Day Variability for concentration 5 µg/mL 
 
ACTUAL 
CONCENTRATION 
µg/mL RT AREA RT AREA RATIO 
MEASURED 
CONCENTRATION  
(µg/mL) 
5 12.152 114244 3.871 262246 0.44 5.7 
5 12.071 110349 3.865 262097 0.42 5.45 
5 12.057 112932 3.866 261373 0.43 5.58 
5 12.071 114547 3.866 264914 0.43 5.58 
5 12.057 119407 3.857 263229 0.45 5..83 
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Appendix III  Data for isoniazid validation 
 Intraday variability for isoniazid concentration 03(µg/mL) 
 
Actual  
concentration(µg/mL) 
 
Measured 
concentration. 
(µg/mL) 
 
 
isoniazid 
RT 
mt 
 
 
 
Area of  
isoniazid 
 
 
Area of IS 
 
 
RT of 
IS 
 
 
Response 
(ratio of 
IS over 
drug) 
 
 
0.3 0.3 1.22 2803.043 12429.162 1.22 0.226 
0.3 0.27 1.22 2756.237 13153.721 1.22 0.21 
0.3 0.29 1.22 2765.588 12451 1.22 0.222 
0.3 0.3 1.22 2951.022 12933.527 1.22 0.228 
0.3 0.29 1.22 2858.498 12806.144 1.22 0.223 
 
Reinjection consistency for concentration0.3µg/mL 
Actual 
concentration 
 Measured 
Concentration 
RT of 
isoniazid 
isoniazid 
Area 
Area of IS RT 
of IS 
RESPONSE 
low QC =0.3 
ug/mL 
0.29 1.22 2176.874 13366.613 1.24 0.163 
Low Qc 0.29 1.22 2124.225 13144.438 1.24 0.162 
Low Qc 0.28 1.22 2103.612 13253.632 1.24 0.159 
Low Qc 0.30 1.22 2103.114 12584.742 1.24 0.167 
Low Qc 0.28 1.22 2086.698 13374.209 1.24 0.156 
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Appendix IV Compliance diary 
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Appendix V - Marginal density plots for isoniazid and rifampicin using Pmetrics 
 Isoniazid marginal density plots 
 
 
Rifampicin marginal density plots 
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Appendix VI- Z scores  
 DATA FOR Z SCORES 
Nutritional status assessment as Z scores  
(No of children) 
No of children 
Height for Age (n=37) 
Less than -3 
Between -2.1 to -3 
-between -1 to -2 
+1 to -1 
 
4 
2 
16 
15 
 
Body mass index (n=37) 
Less than -3 
-2.1 to -3.0 
-1.1to -2.0 
-1 to +1 
 
 
4 
9 
10 
14 
 
Weight for age (n=16) 
Less than -3 
-2 to -3 
0 to -2.01 
 
 
 
1 
2 
13 
 
Note: Weight for age and Weight for height are only for children less than 5 years of 
age. 
Appendix VII patient data for isoniazid and rifampicin 
 
Patient ID Gender Age Weight Height BMI Dose INH D or I t0 t0.5 t1 t1.5 t2 t2.5 t4 t6 Cmax tmax AUC A/D weight 1weight gain
1 2 4.1 13.32 97 14.15 150 1 0 14.44 11.6 9.05 5.7 3 14.4 1 43 3.84 12.3 1.02
2 2 2.5 10.45 88.5 13.3 75 1 0 0.61 2.06 4.29 3.96 2.52 1.2 1 4.29 1.5 11 1.47 9.95 0.5
3 2 4.8 14.73 103 13.9 150 1 0 11.11 8.52 6.83 5.51 4 2 11.1 1 31 3.04 13.8 0.93
4 2 2.3 9.7 79 15.5 75 1 0 6.3 5.63 5.1 3.76 2.8 2 6.3 1 20 2.62 9.4 0.3
5 1 2.5 10.3 81 15.3 75 1 0 4.79 4.45 4.19 3.94 3.9 2 4.79 1 21 2.86 9.86 0.44
6 2 9.6 25 128.5 15.02 300 1 0 0.23 2.02 4.44 8.29 7.6 5.1 3 8.29 2 27 2.28 22.43 2.57
7 1 1.8 10.02 86 13.3 75 1 0 0.92 0.8 0.69 0.64 0.7 0 0.92 1 2.6 0.35 9.6 0.42
8 2 2.5 10.71 90.5 13.1 75 1 0 9.63 7.1 5.65 4.8 3.1 2 9.63 0.5 25 3.57 10.21 0.5
9 2 2 8.12 74 14.8 75 1 0 6.82 5 2.85 1.2 0 6.82 1 14 1.5 7.1 1.02
10 2 5 14.5 94.5 16.2 150 1 1 5.38 3.6 3.17 2.79 2.29 1.4 1 5.38 0.5 13 1.28 13.7 0.8
11 1 12.9 33.1 154 13.95 600 1 0 2.7 5.66 9.4 10.06 8.8 5.6 4 10.1 2 37 2.02 33.5 -0.4
12 2 2.9 13.7 97.5 14.41 150 1 0 3.97 5.7 5.29 4.7 4.14 3.1 2 5.7 1 21 1.95 13.1 0.6
13 2 4.7 16.1 105 14.6 150 1 0 9.6 8.4 7.09 6.29 5.59 3.5 2 9.6 0.5 30 3.19 15.6 0.5
14 2 6.8 19.4 118 13.93 225 1 0 6.68 5.32 7.39 4 3 7.39 2 29 2.53 18.6 0.8
15 1 4.6 14.9 101 14.6 150 1 0 0.55 8.67 6.63 4.2 3 8.67 2 27 2.63 14.2 0.7
16 2 14.1 31 140 14.79 300 1 0 0.79 2 2.77 3.06 2.82 2.2 1 3.06 2 12 1.28 29 2
17 2 15 43 166 15.6 600 1 0 2.91 5.32 8.58 8.54 7.61 5.8 3 8.58 1.5 33 2.39 42.94 0.06
18 2 16.3 49.1 175 16 600 1 0 0.11 1.6 7.11 6.62 5.48 2.9 1 7.11 1.5 20 1.6 45.4 3.7
19 1 4.4 13.16 102 12.64 150 1 0 0.75 4.52 5.68 5.23 3.7 3 5.68 1.5 22 1.95 12.2 0.96
20 1 12.8 27.2 142 13.48 225 1 0 0.84 1.91 1.95 2.19 2.23 2 1 2.23 2.5 10 1.26 26.4 0.8
21 2 3.5 14.2 95 15.73 150 1 0 3.55 3.11 2.82 2.5 1.7 1 3.55 1 12 1.15 13.5 0.7
22 2 11.8 23.4 134.5 12.83 225 1 0 1.17 3.68 4.89 5.8 5.63 4 3 5.8 2 23 2.38 22.5 0.9
23 2 7.1 19.5 128 11.9 150 1 0 2.69 6.91 6.74 5.6 4.98 3.4 2 6.91 1 24 3.1 17.3 2.2
24 1 12.8 37.1 157 15.1 300 2 0 3.72 5.09 5.02 8.15 6.64 4.9 3 8.15 2 30 3.68 33.6 3.5
25 1 14.3 39.9 166.5 14.42 300 2 0 0.12 0.68 3.8 3.2 2.2 1.4 1 3.8 1.5 9.4 1.25 41.3 -1.4
26 1 7.2 22 115.5 16.5 200 2 0 4.66 6.2 5.86 5.7 5.49 4.3 3 6.2 1 27 3.01 18.9 3.1
27 2 15.8 52.45 173 17.5 300 2 0 3.15 2.53 3.05 2.42 2.14 1.3 1 3.15 0.5 11 1.88 49.95 2.5
28 1 13 37.03 158 15.01 300 2 0 1.68 3.3 4.24 4.82 4.89 3.1 2 4.89 2.5 20 2.41 35.5 1.53
29 1 14 41.78 167.5 14.89 300 2 0 9.65 7.62 6.54 5.65 5.45 4.2 3 9.65 0.5 30 4.22 39.98 1.8
30 2 3.3 14.8 98.5 15.3 200 2 0 3.57 7.36 9.96 9.69 8.54 6.4 4 9.96 1.5 39 2.91 13.95 0.85
31 2 6.8 20.92 122.5 13.9 200 2 0 7.89 7.16 6.12 4.37 3.6 1.4 1 7.89 0.5 19 2.02 19.58 1.34
32 2 4 14.86 103 14 130 2 0 2.48 6.58 6.86 6.03 5.08 3.5 2 6.86 1.5 25 2.81 13.5 1.36
33 2 16 46 162 17.5 300 2 0 5.19 5.3 5.01 4.41 4.16 2.9 2 5.3 1 21 3.2 42.2 3.8
34 2 7 19.12 115.5 13.98 200 2 0 6.09 9.25 7.53 6.5 4.98 2.8 1 9.25 1 26 2.48 18.5 0.62
35 2 2 11.88 86 16.1 150 1 0 1.22 4.13 10.9 0.98
RESULTS FOR RIFAMPICIN
Patient ID Gender Age Weight Height BMI Dose rmp D or I t0 t0.5 t1 t1.5 t2 t2.5 t4 t6 Cmax tmax AUC A/D weight 1weight gain
1 2 4.1 13.32 97 14.15 150 1 0 12.07 11.7 9.86 6.1 4 12.1 1 44 3.92 12.3 1.02
2 2 2.5 10.45 88.5 13.3 75 1 0 0.12 0.52 5.19 4.97 3.41 1.8 1 5.19 1.5 12 1.73 9.95 0.5
3 2 4.8 14.73 103 13.9 150 1 0 2.13 4.54 3.1 2.49 1.2 0 4.54 1.5 10 1.02 13.8 0.93
4 2 2.3 9.7 79 15.5 75 1 0 4.2 4.44 3.83 2.27 0.9 0 4.44 1.5 12 1.51 9.4 0.3
5 1 2.5 10.3 81 15.3 75 1 0 1.79 2.36 2.75 2.39 1.8 1 2.75 2 10 1.42 9.86 0.44
6 2 9.6 25 128.5 15.02 300 1 0 0 0.19 0.26 7.51 8.89 5.5 3 8.89 2.5 26 2.15 22.43 2.57
7 1 1.8 10.02 86 13.3 75 1 0 0.19 0.19 0.19 0.19 0.3 1 0.54 6 1.6 0.21 9.6 0.42
8 2 2.5 10.71 90.5 13.1 75 1 0 6.75 7.76 5.88 3.41 1.2 0 7.76 1 17 2.45 10.21 0.5
9 2 2 8.12 74 14.8 75 1 0 6.44 4.29 4.29 1.6 6.44 1 14 1.52 7.1 1.02
10 2 5 14.5 94.5 16.2 150 1 0 0.17 6.19 2.14 1.76 1.51 0.8 0 6.19 0.5 7.9 0.76 13.7 0.8
11 1 12.9 33.1 154 13.95 450 1 0 0 0 0 0 0 0.1 1 1.01 6 1.1 0.08 33.5 -0.4
12 2 2.9 13.7 97.5 14.41 150 1 0 0.44 1.83 4.88 6.55 7.11 5.2 4 7.11 2.5 27 2.48 13.1 0.6
13 2 4.7 16.1 105 14.6 150 1 0 5.44 7.11 5.44 4.75 3.77 2 1 7.11 1 19 2.07 15.6 0.5
14 2 6.8 19.4 118 13.93 225 1 0 7.28 7.1 8.18 3.1 1 8.18 2 29 2.47 18.6 0.8
15 1 4.6 14.9 101 14.6 150 1 0 0.19 7.95 4.58 2.1 2 7.95 2 18 1.78 14.2 0.7
16 2 14.1 31 140 14.79 450 1 0 0.42 1.92 3.17 3.79 3.42 2.4 1 3.79 2 14 0.94 29 2
17 2 15 43 166 15.6 450 1 0 0 0.07 2.67 3.63 3.49 3.9 3 3.9 4 17 1.58 42.94 0.06
18 2 16.3 49.1 175 16 450 1 0 0.07 0.44 2.25 5.44 5.16 3.9 3 5.44 2 19 2.03 45.4 3.7
19 1 4.4 13.16 102 12.64 150 1 0 0 0.75 8.97 7.33 3.5 2 8.97 1.5 23 2.03 12.2 0.96
20 1 12.8 27.2 142 13.48 225 1 0 0 0.9 1.3 2.09 2.39 1.8 1 2.39 2.5 8.6 1.04 26.4 0.8
21 2 3.5 14.2 95 15.73 150 1 0 1.59 1.59 1.5 1.3 0.8 0 1.59 1 5.9 0.56 13.5 0.7
22 2 11.8 23.4 134.5 12.83 225 1 0 2.93 4.82 5.59 6.48 6.04 2.6 1 6.48 2 21 2.22 22.5 0.9
23 2 7.1 19.5 128 11.9 150 1 0 1.59 5.93 6.7 4.7 4.04 1.9 1 6.7 1 18 2.3 17.3 2.2
24 1 12.8 37.1 157 15.1 300 2 0 0 0.23 0.23 0.61 1.49 3.7 2 3.65 4 11 1.3 33.6 3.5
25 1 14.3 39.9 166.5 141.17 450 2 0 0.13 1.64 5.48 5.83 4.43 3.6 3 5.83 2 20 1.8 41.3 -1.4
26 1 7.2 22 115.5 16.5 250 2 0 0.13 1.29 2.57 4.43 4.43 2.3 1 4.43 2 14 1.19 18.9 3.1
27 2 15.8 52.45 173 17.5 450 2 0 0 0 4.43 5.44 5.59 3.6 2 5.59 2.5 18 2.15 49.95 2.5
28 1 13 37.03 158 15.01 450 2 0 0.1 0.22 0.47 3.22 7.72 5.6 3 7.72 2.5 22 1.82 35.5 1.53
29 1 14 41.78 167.5 15 450 2 0 1.23 6.16 12.6 9.96 9.58 7.6 5 12.6 1.5 42 3.94 39.98 1.8
30 2 3.3 14.8 98.5 15.3 200 2 0 0.27 0.6 2.14 2.25 2.03 1.3 1 2.25 2 7.5 0.55 13.95 0.85
31 2 6.8 20.92 122.5 13.9 250 2 0 0.21 0.79 0.56 0.33 0.21 0.1 0 0.79 1 1.3 0.11 19.58 1.34
32 2 4 14.86 103 14 130 2 0 0 0.8 6.98 5.54 4.22 2.4 1 6.98 1.5 17 1.89 13.5 1.36
33 2 16 46 162 17.53 450 2 0 1.5 3.18 5.36 9.12 7.93 6.8 4 9.12 2 34 3.47 42.2 3.8
34 2 7 19.12 115.5 13.98 200 2 0 0.21 1.17 1.89 1.77 1.41 0.8 0 1.89 1.5 5.8 0.55 18.5 0.62
35 2 13 30.9 142.2 15.17 450 1 0 0 0.27 1.18 5.61 7.2 7.3 3 7.31 4 27 1.84 30.6 0.3
36 2 10 19.8 125 12.67 225 1 0 0.15 1.29 19.5 0.3
37 2 2.5 2 11.88 86 150 1 0 0.18 4.39 4.39 2 10.9 0.98
